CDK kinase inhibitor and use thereof

Abstract

A CDK inhibitor having a structure of formula (I), a pharmaceutical composition thereof, the use thereof as a CDK inhibitor, and the use thereof in the preparation of a drug for treating cancers or tumors at least partially associated with CDK. The various substituents in formula (I) are as defined in the description.

Description

A CDK kinase inhibitor and its application Technical Field

[0001] The present invention belongs to the field of drug synthesis, and in particular relates to a CDK kinase inhibitor and an application thereof. Background Art

[0002] Cyclin-dependent kinases (CDKs) are an important class of cellular serine / threonine kinases that play a key role in cell cycle regulation and cellular transcription. The human genome encodes over 20 CDKs, which are divided into two subfamilies: cell cycle-associated CDKs (CDKs 1-7 and 14-18) and transcription-associated CDKs (CDKs 7-13, 19, and 20). Different CDKs interact with different cyclins to regulate multiple phases of the cell cycle or perform other functions.

[0003] The disorder of CDK activity is closely related to the occurrence and development of tumors. Among them, CDK4 and CDK6 are important regulators of the G1 / S node in the cell cycle. They are regulated by D-type cyclins and INK4 endogenous CDK inhibitors (such as p16 INK4a ). Reports have shown that dysregulation of the cyclin D-CDK4 / 6-INK4-retinoblastoma protein (Rb) signaling pathway is associated with resistance to endocrine therapy.

[0004] Breast cancer is the most common malignancy in women, with over 2.3 million new cases globally each year. Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer accounts for 60-70% of all breast cancer cases. Endocrine therapy is one of the mainstays of treatment, but resistance can also occur. In recent years, with the ongoing exploration of reversing endocrine therapy resistance, CDK4 / 6 inhibitors have garnered significant attention since their discovery. CDK4 / 6 inhibitors selectively inhibit CDK4 / 6 kinase activity, arresting the G1 / S phase transition and thereby inhibiting the proliferation of tumor cells. Furthermore, CDK4 / 6 inhibitors can inhibit the expression of the estrogen receptor signaling pathway, creating a synergistic effect with endocrine therapy, delaying and reversing endocrine therapy resistance. The development of CDK4 / 6 inhibitors has revolutionized the traditional approach to endocrine therapy. Combining CDK4 / 6 inhibitors with endocrine therapy has demonstrated significant efficacy in patients with HR-positive, HER2-negative breast cancer, establishing them as the new standard of care for both first- and second-line treatment of patients with HR-positive, HER2-negative breast cancer.

[0005] However, clinical studies have shown that treatment with CDK4 / 6 inhibitors can lead to adverse reactions, such as gastrointestinal and / or hematological toxicity, and acquired drug resistance may develop over time. A growing body of data suggests that hematological toxicity observed clinically is associated with CDK6 / cyclin D3. Furthermore, studies have identified CDK4 as a single oncogenic driver in many breast cancers. In summary, compared to CDK4 / 6 inhibitors, CDK4 selective inhibitors may have better safety and efficacy. Therefore, the development of CDK4 selective inhibitors has high clinical application value.

[0006] Summary of the Invention

[0007] The present invention provides a CDK kinase inhibitor and its application. The compounds of the present invention have a strong inhibitory effect on CDK kinases, especially selective inhibition of CDK4 kinase, and can be widely used in the preparation of drugs for treating at least some cancers or tumors related to CDK.

[0008] The first aspect of the present invention provides a compound of formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof:

[0009] in, Indicates a double bond or a single bond;

[0010] X1 is CR4 or N; X2 is selected from CR5 or N;

[0011] Y is N, CR 6a NR 6b , CR 6c R 6d , O or S;

[0012] Z is N, CR 7a NR 7b , CR 7c R 7d , O or S;

[0013] W is N, CR 8a NR 8b , CR 8c R 8d , O or S;

[0014] Q is N, CR 9a NR 9b , CR 9c R 9d , O or S;

[0015] Ring A is C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl;

[0016] Each R1 is independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, C 3-10 Cycloalkyl substituted C 1-4 Alkyl, 3-10 membered heterocyclic substituted C 1-4 Alkyl, C 6-10 Aryl-substituted C 1-4 Alkyl, 5-10 membered heteroaryl substituted C 1-4 Alkyl, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=NR 10 )R 11 、-C 0-8 Alkyl-N=S(O)R 11 R 12 、-C 0-8 Alkyl-N=SR 11 R 12 、-C 0-8 Alkyl-OS(O)2R 13 、-C 0-8 Alkyl-S(O) r R 13 、-C 0-8 Alkyl-OR 14 、-C 0-8 Alkyl-C(O)OR 14 、-C 0-8 Alkyl-C(O)SR 14 、-C 0-8 Alkyl-SC(O)R 15 、-C 0-8 Alkyl-C(O)R 15 、-C 0-8 Alkyl-OC(O)R 15 、-C 0-8 Alkyl-P(O)(R 15 )2. -C 0-8 Alkyl-NR 16 R 17 、-C 0-8 Alkyl-C(=NR 16 )R 15 、-C 0-8 Alkyl-N(R 16 )-C(=NR 17 )R 15 、-C0-8 Alkyl-C(O)NR 16 R 17 and -C 0-8 Alkyl-N(R 16 )-C(O)R 15 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=NR 10 )R 11 、-C 0-8 Alkyl-N=S(O)R 11 R 12 、-C 0-8 Alkyl-N=SR 11 R 12 、-C 0-8 Alkyl-OS(O)2R 13 、-C 0-8 Alkyl-S(O) r R 13 、-C 0-8 Alkyl-OR 14 、-C 0-8 Alkyl-C(O)OR 14 、-C 0-8 Alkyl-C(O)SR 14 、-C 0-8 Alkyl-SC(O)R 15 、-C 0-8 Alkyl-C(O)R 15 、-C 0-8 Alkyl-OC(O)R 15 、-C 0-8 Alkyl-P(O)(R 15 )2. -C 0-8 Alkyl-NR 16 R 17 、-C 0-8 Alkyl-C(=NR 16 )R 15 、-C 0-8 Alkyl-N(R 16 )-C(=NR 17 )R 15 、-C 0-8 Alkyl-C(O)NR 16 R17 and -C 0-8 Alkyl-N(R 16 )-C(O)R 15 The above groups are independently substituted with one or more substituents selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=NR 10 )R 11 、-C 0-8 Alkyl-N=S(O)R 11 R 12 、-C 0-8 Alkyl-N=SR 11 R 12 、-C 0-8 Alkyl-OS(O)2R 13 、-C 0-8 Alkyl-S(O) r R 13 、-C 0-8 Alkyl-OR 14 、-C 0-8 Alkyl-C(O)OR 14 、-C 0-8 Alkyl-C(O)SR 14 、-C 0-8 Alkyl-SC(O)R 15 、-C 0-8 Alkyl-C(O)R 15 、-C 0-8 Alkyl-OC(O)R 15 、-C 0-8 Alkyl-P(O)(R 15 )2. -C 0-8 Alkyl-NR 16 R 17 、-C 0-8 Alkyl-C(=NR 16 )R 15 、-C 0-8 Alkyl-N(R 16 )-C(=NR 17 )R 15 、-C 0-8 Alkyl-C(O)NR16 R 17 and -C 0-8 Alkyl-N(R 16 )-C(O)R 15 substituted by a substituent;

[0017] R2 is selected from deuterium, halogen, cyano, nitro, azido, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=NR 10 )R 11 、-C 0-4 Alkyl-N=S(O)R 11 R 12 、-C 0-4 Alkyl-N=SR 11 R 12 、-C 0-4 Alkyl-OS(O)2R 13 、-C 0-4 Alkyl-S(O) r R 13 、-C 0-4 Alkyl-OR 14 、-C 0-4 Alkyl-C(O)OR 14 、-C 0-4 Alkyl-C(O)SR 14 、-C 0-4 Alkyl-SC(O)R 15 、-C 0-4 Alkyl-C(O)R 15 、-C 0-4 Alkyl-OC(O)R 15 、-C 0-4 Alkyl-P(O)(R 15 )2. -C 0-4 Alkyl-NR 16 R 17 、-C 0-4 Alkyl-C(=NR 16 )R 15 、-C 0-4 Alkyl-N(R 16 )-C(=NR 17 )R 15 、-C 0-4Alkyl-C(O)NR 16 R 17 and -C 0-4 Alkyl-N(R 16 )-C(O)R 15 , provided that when ring A is C 3-6 When it is a cycloalkyl group or a 3-6 membered heterocyclic group, R2 is not hydrogen;

[0018] R3 is selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=NR 10 )R 11 、-C 0-8 Alkyl-N=S(O)R 11 R 12 、-C 0-8 Alkyl-N=SR 11 R 12 、-C 0-8 Alkyl-OS(O)2R 13 、-C 0-8 Alkyl-S(O) r R 13 、-C 0-8 Alkyl-OR 14 、-C 0-8 Alkyl-C(O)OR 14 、-C 0-8 Alkyl-C(O)SR 14 、-C 0-8 Alkyl-SC(O)R 15 、-C 0-8 Alkyl-C(O)R 15 、-C 0-8 Alkyl-OC(O)R 15 、-C 0-8 Alkyl-P(O)(R 15 )2. -C 0-8 Alkyl-NR 16 R 17 、-C 0-8 Alkyl-C(=NR 16 )R 15 、-C 0-8 Alkyl-N(R 16)-C(=NR 17 )R 15 、-C 0-8 Alkyl-C(O)NR 16 R 17 and -C 0-8 Alkyl-N(R 16 )-C(O)R 15 ;

[0019] R4 is selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=NR 10 )R 11 、-C 0-8 Alkyl-N=S(O)R 11 R 12 、-C 0-8 Alkyl-N=SR 11 R 12 、-C 0-8 Alkyl-OS(O)2R 13 、-C 0-8 Alkyl-S(O) r R 13 、-C 0-8 Alkyl-OR 14 、-C 0-8 Alkyl-C(O)OR 14 、-C 0-8 Alkyl-C(O)SR 14 、-C 0-8 Alkyl-SC(O)R 15 、-C 0-8 Alkyl-C(O)R 15 、-C 0-8 Alkyl-OC(O)R 15 、-C 0-8 Alkyl-P(O)(R 15 )2. -C 0-8 Alkyl-NR 16 R 17 、-C 0-8 Alkyl-C(=NR 16 )R 15 、-C 0-8 Alkyl-N(R16 )-C(=NR 17 )R 15 、-C 0-8 Alkyl-C(O)NR 16 R 17 and -C 0-8 Alkyl-N(R 16 )-C(O)R 15 ;

[0020] R5 is selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=NR 10 )R 11 、-C 0-8 Alkyl-N=S(O)R 11 R 12 、-C 0-8 Alkyl-N=SR 11 R 12 、-C 0-8 Alkyl-OS(O)2R 13 、-C 0-8 Alkyl-S(O) r R 13 、-C 0-8 Alkyl-OR 14 、-C 0-8 Alkyl-C(O)OR 14 、-C 0-8 Alkyl-C(O)SR 14 、-C 0-8 Alkyl-SC(O)R 15 、-C 0-8 Alkyl-C(O)R 15 、-C 0-8 Alkyl-OC(O)R 15 、-C 0-8 Alkyl-P(O)(R 15 )2. -C 0-8 Alkyl-NR 16 R 17 、-C 0-8 Alkyl-C(=NR 16 )R 15 、-C 0-8Alkyl-N(R 16 )-C(=NR 17 )R 15 、-C 0-8 Alkyl-C(O)NR 16 R 17 and -C 0-8 Alkyl-N(R 16 )-C(O)R 15 ;

[0021] R 6a 、R 7a 、R 8a and R 9a are each independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=NR 10 )R 11 、-C 0-8 Alkyl-N=S(O)R 11 R 12 、-C 0-8 Alkyl-N=SR 11 R 12 、-C 0-8 Alkyl-OS(O)2R 13 、-C 0-8 Alkyl-S(O) r R 13 、-C 0-8 Alkyl-OR 14 、-C 0-8 Alkyl-C(O)OR 14 、-C 0-8 Alkyl-C(O)SR 14 、-C 0-8 Alkyl-SC(O)R 15 、-C 0-8 Alkyl-C(O)R 15 、-C 0-8 Alkyl-OC(O)R 15 、-C 0-8 Alkyl-P(O)(R 15 )2. -C 0-8 Alkyl-NR 16 R 17 、-C 0-8 Alkyl-C(=NR 16 )R15 、-C 0-8 Alkyl-N(R 16 )-C(=NR 17 )R 15 、-C 0-8 Alkyl-C(O)NR 16 R 17 and -C 0-8 Alkyl-N(R 16 )-C(O)R 15 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=NR 10 )R 11 、-C 0-8 Alkyl-N=S(O)R 11 R 12 、-C 0-8 Alkyl-N=SR 11 R 12 、-C 0-8 Alkyl-OS(O)2R 13 、-C 0-8 Alkyl-S(O) r R 13 、-C 0-8 Alkyl-OR 14 、-C 0-8 Alkyl-C(O)OR 14 、-C 0-8 Alkyl-C(O)SR 14 、-C 0-8 Alkyl-SC(O)R 15 、-C 0-8 Alkyl-C(O)R 15 、-C 0-8 Alkyl-OC(O)R 15 、-C 0-8 Alkyl-P(O)(R 15 )2. -C 0-8 Alkyl-NR 16 R 17 、-C 0-8 Alkyl-C(=NR 16 )R 15 、-C 0-8 Alkyl-N(R16 )-C(=NR 17 )R 15 、-C 0-8 Alkyl-C(O)NR 16 R 17 and -C 0-8 Alkyl-N(R 16 )-C(O)R 15 The above groups are independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=NR 10 )R 11 、-C 0-8 Alkyl-N=S(O)R 11 R 12 、-C 0-8 Alkyl-N=SR 11 R 12 、-C 0-8 Alkyl-OS(O)2R 13 、-C 0-8 Alkyl-S(O) r R 13 、-C 0-8 Alkyl-OR 14 、-C 0-8 Alkyl-C(O)OR 14 、-C 0-8 Alkyl-C(O)SR 14 、-C 0-8 Alkyl-SC(O)R 15 、-C 0-8 Alkyl-C(O)R 15 、-C 0-8 Alkyl-OC(O)R 15 、-C 0-8 Alkyl-P(O)(R 15 )2. -C 0-8 Alkyl-NR 16 R 17 、-C 0-8 Alkyl-C(=NR 16 )R 15 、-C 0-8Alkyl-N(R 16 )-C(=NR 17 )R 15 、-C 0-8 Alkyl-C(O)NR 16 R 17 and -C 0-8 Alkyl-N(R 16 )-C(O)R 15 substituted by a substituent;

[0022] R 6b 、R 7b 、R 8b and R 9b Selected from hydrogen, deuterium, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-S(O)(=NR 10 )R 11 、-C 0-8 Alkyl-S(O) r R 13 、-C 0-8 Alkyl-C(O)OR 14 、-C 0-8 Alkyl-C(O)SR 14 、-C 0-8 Alkyl-C(O)R 15 、-C 0-8 Alkyl-P(O)(R 15 )2. -C 0-8 Alkyl-C(=NR 16 )R 15 and -C 0-8 Alkyl-C(O)NR 16 R 17 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=NR 10 )R 11 、-C0-8 Alkyl-N=S(O)R 11 R 12 、-C 0-8 Alkyl-N=SR 11 R 12 、-C 0-8 Alkyl-OS(O)2R 13 、-C 0-8 Alkyl-S(O) r R 13 、-C 0-8 Alkyl-OR 14 、-C 0-8 Alkyl-C(O)OR 14 、-C 0-8 Alkyl-C(O)SR 14 、-C 0-8 Alkyl-SC(O)R 15 、-C 0-8 Alkyl-C(O)R 15 、-C 0-8 Alkyl-OC(O)R 15 、-C 0-8 Alkyl-P(O)(R 15 )2. -C 0-8 Alkyl-NR 16 R 17 、-C 0-8 Alkyl-C(=NR 16 )R 15 、-C 0-8 Alkyl-N(R 16 )-C(=NR 17 )R 15 、-C 0-8 Alkyl-C(O)NR 16 R 17 and -C 0-8 Alkyl-N(R 16 )-C(O)R 15 substituted by a substituent;

[0023] Or, R 6b and R 7a Together with the part directly connected thereto, a 3-10 membered heterocyclic group or a 5-10 membered heteroaryl group is formed, wherein the above 3-10 membered heterocyclic group or the 5-10 membered heteroaryl group is independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=NR 10 )R 11 、-C 0-8 Alkyl-N=S(O)R 11 R 12 、-C 0-8 Alkyl-N=SR 11 R 12 、-C 0-8 Alkyl-OS(O)2R 13 、-C 0-8 Alkyl-S(O) r R 13 、-C 0-8 Alkyl-OR 14 、-C 0-8 Alkyl-C(O)OR 14 、-C 0-8 Alkyl-C(O)SR 14 、-C 0-8 Alkyl-SC(O)R 15 、-C 0-8 Alkyl-C(O)R 15 、-C 0-8 Alkyl-OC(O)R 15 、-C 0-8 Alkyl-P(O)(R 15 )2. -C 0-8 Alkyl-NR 16 R 17 、-C 0-8 Alkyl-C(=NR 16 )R 15 、-C 0-8 Alkyl-N(R 16 )-C(=NR 17 )R 15 、-C 0-8 Alkyl-C(O)NR 16 R 17 and -C 0-8 Alkyl-N(R 16 )-C(O)R 15 substituted by a substituent;

[0024] Or, R 6a and R 7b Together with the part directly connected thereto, a 3-10 membered heterocyclic group or a 5-10 membered heteroaryl group is formed, wherein the above 3-10 membered heterocyclic group or the 5-10 membered heteroaryl group is independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, nitro, azido, C1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=NR 10 )R 11 、-C 0-8 Alkyl-N=S(O)R 11 R 12 、-C 0-8 Alkyl-N=SR 11 R 12 、-C 0-8 Alkyl-OS(O)2R 13 、-C 0-8 Alkyl-S(O) r R 13 、-C 0-8 Alkyl-OR 14 、-C 0-8 Alkyl-C(O)OR 14 、-C 0-8 Alkyl-C(O)SR 14 、-C 0-8 Alkyl-SC(O)R 15 、-C 0-8 Alkyl-C(O)R 15 、-C 0-8 Alkyl-OC(O)R 15 、-C 0-8 Alkyl-P(O)(R 15 )2. -C 0-8 Alkyl-NR 16 R 17 、-C 0-8 Alkyl-C(=NR 16 )R 15 、-C 0-8 Alkyl-N(R 16 )-C(=NR 17 )R 15 、-C 0-8 Alkyl-C(O)NR 16 R 17 and -C 0-8 Alkyl-N(R 16 )-C(O)R 15 substituted by a substituent;

[0025] R6c 、R 6d 、R 7c 、R 7d 、R 8c 、R 8d 、R 9c and R 9d are each independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=NR 10 )R 11 、-C 0-8 Alkyl-N=S(O)R 11 R 12 、-C 0-8 Alkyl-N=SR 11 R 12 、-C 0-8 Alkyl-OS(O)2R 13 、-C 0-8 Alkyl-S(O) r R 13 、-C 0-8 Alkyl-OR 14 、-C 0-8 Alkyl-C(O)OR 14 、-C 0-8 Alkyl-C(O)SR 14 、-C 0-8 Alkyl-SC(O)R 15 、-C 0-8 Alkyl-C(O)R 15 、-C 0-8 Alkyl-OC(O)R 15 、-C 0-8 Alkyl-P(O)(R 15 )2. -C 0-8 Alkyl-NR 16 R 17 、-C 0-8 Alkyl-C(=NR 16 )R 15 、-C 0-8 Alkyl-N(R 16 )-C(=NR 17 )R 15 、-C 0-8 Alkyl-C(O)NR 16 R17 and -C 0-8 Alkyl-N(R 16 )-C(O)R 15 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=NR 10 )R 11 、-C 0-8 Alkyl-N=S(O)R 11 R 12 、-C 0-8 Alkyl-N=SR 11 R 12 、-C 0-8 Alkyl-OS(O)2R 13 、-C 0-8 Alkyl-S(O) r R 13 、-C 0-8 Alkyl-OR 14 、-C 0-8 Alkyl-C(O)OR 14 、-C 0-8 Alkyl-C(O)SR 14 、-C 0-8 Alkyl-SC(O)R 15 、-C 0-8 Alkyl-C(O)R 15 、-C 0-8 Alkyl-OC(O)R 15 、-C 0-8 Alkyl-P(O)(R 15 )2. -C 0-8 Alkyl-NR 16 R 17 、-C 0-8 Alkyl-C(=NR 16 )R 15 、-C 0-8 Alkyl-N(R 16 )-C(=NR 17 )R 15 、-C 0-8 Alkyl-C(O)NR 16 R17 and -C 0-8 Alkyl-N(R 16 )-C(O)R 15 substituted by a substituent;

[0026] Each R 10 are each independently selected from hydrogen, deuterium, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-S(O) r R 13 、-C 0-8 Alkyl-C(O)OR 14 、-C 0-8 Alkyl-C(O)R 15 and -C 0-8 Alkyl-C(O)NR 16 R 17 The above groups are optionally further substituted by one or more groups selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, halogen-substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-S(O) r R 13 、-C 0-8 Alkyl-OR 14 、-C 0-8 Alkyl-C(O)OR 14 、-C 0-8 Alkyl-C(O)R 15 、-C 0-8 Alkyl-OC(O)R 15 、-C 0-8 Alkyl-NR 16 R 17 、-C 0-8 Alkyl-C(=NR 16 )R 15 、-C 0-8 Alkyl-N(R 16 )-C(=NR 17 )R 15 、-C 0-8 Alkyl-C(O)NR 16 R17 and -C 0-8 Alkyl-N(R 16 )-C(O)R 15 substituted by a substituent;

[0027] Each R 11 and each R 12 are independently selected from hydrogen, deuterium, hydroxyl, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, or R 11 and R 12 Together with the sulfur atom directly connected thereto, a 3-10 membered heterocyclic group is formed, wherein the above group is optionally further substituted with one or more selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, halogen-substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-S(O) r R 13 、-C 0-8 Alkyl-OR 14 、-C 0-8 Alkyl-C(O)OR 14 、-C 0-8 Alkyl-C(O)R 15 、-C 0-8 Alkyl-OC(O)R 15 、-C 0-8 Alkyl-NR 16 R 17 、-C 0-8 Alkyl-C(=NR 16 )R 15 、-C 0-8 Alkyl-N(R 16 )-C(=NR 17 )R 15 、-C 0-8 Alkyl-C(O)NR 16 R 17 and -C 0-8 Alkyl-N(R 16 )-C(O)R 15 substituted by a substituent;

[0028] Each R13 independently selected from hydrogen, deuterium, hydroxyl, C 1-10 Alkyl, C 2-10 Alkenyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl and -NR 16 R 17 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, hydroxyl, =O, C 1-10 Alkyl, C 1-10 Alkoxy, C 3-12 Cycloalkyl, C 3-12 Cycloalkoxy, 3-12 membered heterocyclic group, 3-12 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy and -NR 16 R 17 substituted by a substituent;

[0029] Each R 14 independently selected from hydrogen, deuterium, C 1-10 Alkyl, C 2-10 Alkenyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, cyano, C 1-10 Alkyl, C 1-10 Alkoxy, C 3-12 Cycloalkyl, C 3-12 Cycloalkoxy, 3-12 membered heterocyclic group, 3-12 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy and -NR 16 R 17 substituted by a substituent;

[0030] Each R 15 independently selected from hydrogen, deuterium, hydroxyl, C 1-10 Alkyl, C 1-10 Alkoxy, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, C 3-12 Cycloalkoxy, 3-12 membered heterocyclic group, 3-12 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy and -NR 16 R 17The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, cyano, C 1-10 Alkyl, C 1-10 Alkoxy, C 3-12 Cycloalkyl, C 3-12 Cycloalkoxy, 3-12 membered heterocyclic group, 3-12 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy and -NR 16 R 17 substituted by a substituent;

[0031] Each R 16 and R 17 are independently selected from hydrogen, deuterium, hydroxyl, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, sulfinyl, sulfonyl, methylsulfonyl, isopropylsulfonyl, cyclopropylsulfonyl, p-toluenesulfonyl, aminosulfonyl, dimethylaminosulfonyl and C 1-10 Alkanoyl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, halogen-substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 1-10 Alkoxy, C 3-12 Cycloalkyl, C 3-12 Cycloalkoxy, 3-12 membered heterocyclic group, 3-12 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy, amino, mono C 1-10 Alkylamino, di-C 1-10 Alkylamino and C 1-10 substituted with an alkanoyl substituent;

[0032] Or, R 16 and R 17 Together with the nitrogen atom directly connected thereto, a 4-10 membered heterocyclic group or a 5-10 membered heteroaryl group is formed, wherein the 4-10 membered heterocyclic group or the 5-10 membered heteroaryl group is optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, ═O, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, halogen-substituted C 1-10 Alkyl, deuterium substituted C1-10 Alkyl, C 1-10 Alkoxy, C 3-12 Cycloalkyl, C 3-12 Cycloalkoxy, 3-12 membered heterocyclic group, 3-12 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy, amino, mono C 1-10 Alkylamino, di-C 1-10 Alkylamino and C 1-10 substituted with an alkanoyl substituent;

[0033] m is 0, 1, 2 or 3; and, each r is independently 0, 1 or 2.

[0034] As a preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, each R1 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, C 3-6 Cycloalkyl substituted C 1-4 Alkyl, 3-6 membered heterocyclic substituted C 1-4 Alkyl, C 6-8 Aryl-substituted C 1-4 Alkyl, 5-8 membered heteroaryl substituted C 1-4 Alkyl, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=NR 10 )R 11 、-C 0-4 Alkyl-N=S(O)R 11 R 12 、-C 0-4 Alkyl-N=SR 11 R 12 、-C 0-4 Alkyl-OS(O)2R 13 、-C 0-4 Alkyl-S(O) r R 13 、-C 0-4 Alkyl-OR 14 、-C 0-4 Alkyl-C(O)OR 14 、-C 0-4 Alkyl-C(O)SR 14 、-C 0-4 Alkyl-SC(O)R 15 、-C0-4 Alkyl-C(O)R 15 、-C 0-4 Alkyl-OC(O)R 15 、-C 0-4 Alkyl-P(O)(R 15 )2. -C 0-4 Alkyl-NR 16 R 17 、-C 0-4 Alkyl-C(=NR 16 )R 15 、-C 0-4 Alkyl-N(R 16 )-C(=NR 17 )R 15 、-C 0-4 Alkyl-C(O)NR 16 R 17 and -C 0-4 Alkyl-N(R 16 )-C(O)R 15 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=NR 10 )R 11 、-C 0-4 Alkyl-N=S(O)R 11 R 12 、-C 0-4 Alkyl-N=SR 11 R 12 、-C 0-4 Alkyl-OS(O)2R 13 、-C 0-4 Alkyl-S(O) r R 13 、-C 0-4 Alkyl-OR 14 、-C 0-4 Alkyl-C(O)OR 14 、-C 0-4 Alkyl-C(O)SR 14 、-C 0-4 Alkyl-SC(O)R 15 、-C 0-4 Alkyl-C(O)R 15 、-C 0-4Alkyl-OC(O)R 15 、-C 0-4 Alkyl-P(O)(R 15 )2. -C 0-4 Alkyl-NR 16 R 17 、-C 0-4 Alkyl-C(=NR 16 )R 15 、-C 0-4 Alkyl-N(R 16 )-C(=NR 17 )R 15 、-C 0-4 Alkyl-C(O)NR 16 R 17 and -C 0-4 Alkyl-N(R 16 )-C(O)R 15 The above groups are independently substituted with one or more substituents selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=NR 10 )R 11 、-C 0-4 Alkyl-N=S(O)R 11 R 12 、-C 0-4 Alkyl-N=SR 11 R 12 、-C 0-4 Alkyl-OS(O)2R 13 、-C 0-4 Alkyl-S(O) r R 13 、-C 0-4 Alkyl-OR 14 、-C 0-4 Alkyl-C(O)OR 14 、-C 0-4 Alkyl-C(O)SR 14 、-C 0-4 Alkyl-SC(O)R 15 、-C 0-4 Alkyl-C(O)R 15 、-C 0-4Alkyl-OC(O)R 15 、-C 0-4 Alkyl-P(O)(R 15 )2. -C 0-4 Alkyl-NR 16 R 17 、-C 0-4 Alkyl-C(=NR 16 )R 15 、-C 0-4 Alkyl-N(R 16 )-C(=NR 17 )R 15 、-C 0-4 Alkyl-C(O)NR 16 R 17 and -C 0-4 Alkyl-N(R 16 )-C(O)R 15 substituted by a substituent;

[0035] R2 is selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -SF5, -S(O)(=NR 10 )R 11 、-N=S(O)R 11 R 12 、-N=SR 11 R 12 、-OS(O)2R 13 、-S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)SR 14 、-SC(O)R 15 、-C(O)R 15 、-OC(O)R 15 、-P(O)(R 15 )2、-NR 16 R 17 、-C(=NR 16 )R 15 、-N(R 16 )-C(=NR 17 )R 15 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R15 , provided that when ring A is C 3-6 When it is a cycloalkyl group or a 3-6 membered heterocyclic group, R2 is not hydrogen;

[0036] R3 is selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=NR 10 )R 11 、-C 0-4 Alkyl-N=S(O)R 11 R 12 、-C 0-4 Alkyl-N=SR 11 R 12 、-C 0-4 Alkyl-OS(O)2R 13 、-C 0-4 Alkyl-S(O) r R 13 、-C 0-4 Alkyl-OR 14 、-C 0-4 Alkyl-C(O)OR 14 、-C 0-4 Alkyl-C(O)SR 14 、-C 0-4 Alkyl-SC(O)R 15 、-C 0-4 Alkyl-C(O)R 15 、-C 0-4 Alkyl-OC(O)R 15 、-C 0-4 Alkyl-P(O)(R 15 )2. -C 0-4 Alkyl-NR 16 R 17 、-C 0-4 Alkyl-C(=NR 16 )R 15 、-C 0-4 Alkyl-N(R 16 )-C(=NR 17 )R 15 、-C 0-4 Alkyl-C(O)NR 16 R 17 and -C0-4 Alkyl-N(R 16 )-C(O)R 15 ;

[0037] R4 is selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=NR 10 )R 11 、-C 0-4 Alkyl-N=S(O)R 11 R 12 、-C 0-4 Alkyl-N=SR 11 R 12 、-C 0-4 Alkyl-OS(O)2R 13 、-C 0-4 Alkyl-S(O) r R 13 、-C 0-4 Alkyl-OR 14 、-C 0-4 Alkyl-C(O)OR 14 、-C 0-4 Alkyl-C(O)SR 14 、-C 0-4 Alkyl-SC(O)R 15 、-C 0-4 Alkyl-C(O)R 15 、-C 0-4 Alkyl-OC(O)R 15 、-C 0-4 Alkyl-P(O)(R 15 )2. -C 0-4 Alkyl-NR 16 R 17 、-C 0-4 Alkyl-C(=NR 16 )R 15 、-C 0-4 Alkyl-N(R 16 )-C(=NR 17 )R 15 、-C 0-4 Alkyl-C(O)NR 16 R 17 and -C0-4 Alkyl-N(R 16 )-C(O)R 15 ;

[0038] R5 is selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=NR 10 )R 11 、-C 0-4 Alkyl-N=S(O)R 11 R 12 、-C 0-4 Alkyl-N=SR 11 R 12 、-C 0-4 Alkyl-OS(O)2R 13 、-C 0-4 Alkyl-S(O) r R 13 、-C 0-4 Alkyl-OR 14 、-C 0-4 Alkyl-C(O)OR 14 、-C 0-4 Alkyl-C(O)SR 14 、-C 0-4 Alkyl-SC(O)R 15 、-C 0-4 Alkyl-C(O)R 15 、-C 0-4 Alkyl-OC(O)R 15 、-C 0-4 Alkyl-P(O)(R 15 )2. -C 0-4 Alkyl-NR 16 R 17 、-C 0-4 Alkyl-C(=NR 16 )R 15 、-C 0-4 Alkyl-N(R 16 )-C(=NR 17 )R 15 、-C 0-4 Alkyl-C(O)NR 16 R 17 and -C0-4 Alkyl-N(R 16 )-C(O)R 15 ;

[0039] R 6a 、R 7a 、R 8a and R 9a are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=NR 10 )R 11 、-C 0-4 Alkyl-N=S(O)R 11 R 12 、-C 0-4 Alkyl-N=SR 11 R 12 、-C 0-4 Alkyl-OS(O)2R 13 、-C 0-4 Alkyl-S(O) r R 13 、-C 0-4 Alkyl-OR 14 、-C 0-4 Alkyl-C(O)OR 14 、-C 0-4 Alkyl-C(O)SR 14 、-C 0-4 Alkyl-SC(O)R 15 、-C 0-4 Alkyl-C(O)R 15 、-C 0-4 Alkyl-OC(O)R 15 、-C 0-4 Alkyl-P(O)(R 15 )2. -C 0-4 Alkyl-NR 16 R 17 、-C 0-4 Alkyl-C(=NR 16 )R 15 、-C 0-4 Alkyl-N(R 16 )-C(=NR 17 )R 15 、-C 0-4 Alkyl-C(O)NR 16R 17 and -C 0-4 Alkyl-N(R 16 )-C(O)R 15 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=NR 10 )R 11 、-C 0-4 Alkyl-N=S(O)R 11 R 12 、-C 0-4 Alkyl-N=SR 11 R 12 、-C 0-4 Alkyl-OS(O)2R 13 、-C 0-4 Alkyl-S(O) r R 13 、-C 0-4 Alkyl-OR 14 、-C 0-4 Alkyl-C(O)OR 14 、-C 0-4 Alkyl-C(O)SR 14 、-C 0-4 Alkyl-SC(O)R 15 、-C 0-4 Alkyl-C(O)R 15 、-C 0-4 Alkyl-OC(O)R 15 、-C 0-4 Alkyl-P(O)(R 15 )2. -C 0-4 Alkyl-NR 16 R 17 、-C 0-4 Alkyl-C(=NR 16 )R 15 、-C 0-4 Alkyl-N(R 16 )-C(=NR 17 )R 15 、-C 0-4 Alkyl-C(O)NR 16 R 17 and -C 0-4 Alkyl-N(R 16)-C(O)R 15 The above groups are independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=NR 10 )R 11 、-C 0-4 Alkyl-N=S(O)R 11 R 12 、-C 0-4 Alkyl-N=SR 11 R 12 、-C 0-4 Alkyl-OS(O)2R 13 、-C 0-4 Alkyl-S(O) r R 13 、-C 0-4 Alkyl-OR 14 、-C 0-4 Alkyl-C(O)OR 14 、-C 0-4 Alkyl-C(O)SR 14 、-C 0-4 Alkyl-SC(O)R 15 、-C 0-4 Alkyl-C(O)R 15 、-C 0-4 Alkyl-OC(O)R 15 、-C 0-4 Alkyl-P(O)(R 15 )2. -C 0-4 Alkyl-NR 16 R 17 、-C 0-4 Alkyl-C(=NR 16 )R 15 、-C 0-4 Alkyl-N(R 16 )-C(=NR 17 )R 15 、-C 0-4 Alkyl-C(O)NR 16 R 17 and -C 0-4 Alkyl-N(R 16)-C(O)R 15 substituted by a substituent;

[0040] R 6b 、R 7b 、R 8b and R 9b Selected from hydrogen, deuterium, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C 0-4 Alkyl-S(O)(=NR 10 )R 11 、-C 0-4 Alkyl-S(O) r R 13 、-C 0-4 Alkyl-C(O)OR 14 、-C 0-4 Alkyl-C(O)SR 14 、-C 0-4 Alkyl-C(O)R 15 、-C 0-4 Alkyl-P(O)(R 15 )2. -C 0-4 Alkyl-C(=NR 16 )R 15 and -C 0-4 Alkyl-C(O)NR 16 R 17 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=NR 10 )R 11 、-C 0-4 Alkyl-N=S(O)R 11 R 12 、-C 0-4 Alkyl-N=SR 11 R 12 、-C 0-4 Alkyl-OS(O)2R 13 、-C 0-4Alkyl-S(O) r R 13 、-C 0-4 Alkyl-OR 14 、-C 0-4 Alkyl-C(O)OR 14 、-C 0-4 Alkyl-C(O)SR 14 、-C 0-4 Alkyl-SC(O)R 15 、-C 0-4 Alkyl-C(O)R 15 、-C 0-4 Alkyl-OC(O)R 15 、-C 0-4 Alkyl-P(O)(R 15 )2. -C 0-4 Alkyl-NR 16 R 17 、-C 0-4 Alkyl-C(=NR 16 )R 15 、-C 0-4 Alkyl-N(R 16 )-C(=NR 17 )R 15 、-C 0-4 Alkyl-C(O)NR 16 R 17 and -C 0-4 Alkyl-N(R 16 )-C(O)R 15 substituted by a substituent;

[0041] Or, R 6b and R 7a Together with the part directly connected thereto, a 3-8 membered heterocyclic group or a 5-8 membered heteroaryl group is formed, wherein the above 3-8 membered heterocyclic group or the 5-8 membered heteroaryl group is independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=NR 10 )R 11 、-C 0-4 Alkyl-N=S(O)R 11 R 12 、-C0-4 Alkyl-N=SR 11 R 12 、-C 0-4 Alkyl-OS(O)2R 13 、-C 0-4 Alkyl-S(O) r R 13 、-C 0-4 Alkyl-OR 14 、-C 0-4 Alkyl-C(O)OR 14 、-C 0-4 Alkyl-C(O)SR 14 、-C 0-4 Alkyl-SC(O)R 15 、-C 0-4 Alkyl-C(O)R 15 、-C 0-4 Alkyl-OC(O)R 15 、-C 0-4 Alkyl-P(O)(R 15 )2. -C 0-4 Alkyl-NR 16 R 17 、-C 0-4 Alkyl-C(=NR 16 )R 15 、-C 0-4 Alkyl-N(R 16 )-C(=NR 17 )R 15 、-C 0-4 Alkyl-C(O)NR 16 R 17 and -C 0-4 Alkyl-N(R 16 )-C(O)R 15 substituted by a substituent;

[0042] Or, R 6a and R 7b Together with the part directly connected thereto, a 3-8 membered heterocyclic group or a 5-8 membered heteroaryl group is formed, wherein the above 3-8 membered heterocyclic group or the 5-8 membered heteroaryl group is independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4Alkyl-S(O)(=NR 10 )R 11 、-C 0-4 Alkyl-N=S(O)R 11 R 12 、-C 0-4 Alkyl-N=SR 11 R 12 、-C 0-4 Alkyl-OS(O)2R 13 、-C 0-4 Alkyl-S(O) r R 13 、-C 0-4 Alkyl-OR 14 、-C 0-4 Alkyl-C(O)OR 14 、-C 0-4 Alkyl-C(O)SR 14 、-C 0-4 Alkyl-SC(O)R 15 、-C 0-4 Alkyl-C(O)R 15 、-C 0-4 Alkyl-OC(O)R 15 、-C 0-4 Alkyl-P(O)(R 15 )2. -C 0-4 Alkyl-NR 16 R 17 、-C 0-4 Alkyl-C(=NR 16 )R 15 、-C 0-4 Alkyl-N(R 16 )-C(=NR 17 )R 15 、-C 0-4 Alkyl-C(O)NR 16 R 17 and -C 0-4 Alkyl-N(R 16 )-C(O)R 15 substituted by a substituent;

[0043] Among them, R 10 、R 11 、R 12 、R 13 、R 14 、R 15 、R 16 、R 17 and r are as described for the compound of formula (I).

[0044] As a preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts, each R 10 are each independently selected from hydrogen, deuterium, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C 0-4 Alkyl-S(O) r R 13 、-C 0-4 Alkyl-C(O)OR 14 、-C 0-4 Alkyl-C(O)R 15 and -C 0-4 Alkyl-C(O)NR 16 R 17 The above groups are optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, halogen-substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C 0-4 Alkyl-S(O) r R 13 、-C 0-4 Alkyl-OR 14 、-C 0-4 Alkyl-C(O)OR 14 、-C 0-4 Alkyl-C(O)R 15 、-C 0-4 Alkyl-OC(O)R 15 、-C 0-4 Alkyl-NR 16 R 17 、-C 0-4 Alkyl-C(=NR 16 )R 15 、-C 0-4 Alkyl-N(R 16 )-C(=NR 17 )R 15 、-C 0-4 Alkyl-C(O)NR 16 R 17 and -C 0-4 Alkyl-N(R 16 )-C(O)R 15 substituted by a substituent;

[0045] Each R 11 and each R 12 are independently selected from hydrogen, deuterium, hydroxyl, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl and 5-8 membered heteroaryl, or R 11 and R 12 Together with the sulfur atom directly connected thereto, a 3-8 membered heterocyclic group is formed, wherein the above group is optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, halogen-substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C 0-4 Alkyl-S(O) r R 13 、-C 0-4 Alkyl-OR 14 、-C 0-4 Alkyl-C(O)OR 14 、-C 0-4 Alkyl-C(O)R 15 、-C 0-4 Alkyl-OC(O)R 15 、-C 0-4 Alkyl-NR 16 R 17 、-C 0-4 Alkyl-C(=NR 16 )R 15 、-C 0-4 Alkyl-N(R 16 )-C(=NR 17 )R 15 、-C 0-4 Alkyl-C(O)NR 16 R 17 and -C 0-4 Alkyl-N(R 16 )-C(O)R 15 substituted by a substituent;

[0046] Each R 13 independently selected from hydrogen, deuterium, hydroxyl, C 1-4 Alkyl, C 2-4 Alkenyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C6-8 Aryl, 5-8 membered heteroaryl and -NR 16 R 17 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, hydroxyl, =O, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy and -NR 16 R 17 substituted by a substituent;

[0047] Each R 14 independently selected from hydrogen, deuterium, C 1-4 Alkyl, C 2-4 Alkenyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl and 5-8 membered heteroaryl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, cyano, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy and -NR 16 R 17 substituted by a substituent;

[0048] Each R 15 independently selected from hydrogen, deuterium, hydroxyl, C 1-4 Alkyl, C 1-4 Alkoxy, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy and -NR 16 R 17 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, cyano, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy and -NR 16 R 17 substituted by a substituent;

[0049] Each R 16 and R 17 are independently selected from hydrogen, deuterium, hydroxyl, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, sulfinyl, sulfonyl, methylsulfonyl, isopropylsulfonyl, cyclopropylsulfonyl, p-toluenesulfonyl, aminosulfonyl, dimethylaminosulfonyl and C 1-4 Alkanoyl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, halogen-substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, amino, mono C 1-4 Alkylamino, di-C 1-4 Alkylamino and C 1-4 substituted with an alkanoyl substituent;

[0050] Or, R 16 and R 17 Together with the nitrogen atom directly connected thereto, a 4-6 membered heterocyclic group or a 5-8 membered heteroaryl group is formed, wherein the 4-6 membered heterocyclic group or the 5-8 membered heteroaryl group is optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, ═O, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, halogen-substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, amino, mono C 1-4 Alkylamino, di-C 1-4 Alkylamino and C 1-4 The alkanoyl group is substituted with an alkanoyl substituent.

[0051] As a further preferred embodiment, among the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, the compound of formula (I) is the following formula (IIa1), formula (IIa2), formula (IIa3) or formula (IIa4):

[0052] wherein each X1 is independently CR4 or N;

[0053] Each W is independently N or CR 8a ;

[0054] Each Q is independently N or CR 9a ;

[0055] Each ring A is independently C 5-8 Cycloalkyl or 5-8 membered heterocyclic group;

[0056] Each R1 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -S(O)(=NR 10 )R 11 、-N=S(O)R 11 R 12 、-N=SR 11 R 12 、-OS(O)2R 13 、-S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)SR 14 、-SC(O)R 15 、-C(O)R 15 、-OC(O)R 15 、-P(O)(R 15 )2、-NR 16 R 17 、-C(=NR 16 )R 15 、-N(R 16 )-C(=NR 17 )R15 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -S(O)(=NR 10 )R 11 、-N=S(O)R 11 R 12 、-N=SR 11 R 12 、-OS(O)2R 13 、-S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)SR 14 、-SC(O)R 15 、-C(O)R 15 、-OC(O)R 15 、-P(O)(R 15 )2、-NR 16 R 17 、-C(=NR 16 )R 15 、-N(R 16 )-C(=NR 17 )R 15 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 substituted by a substituent;

[0057] Each R2 is independently selected from halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 1-4 Alkoxy, halogen substituted C 1-4 Alkoxy, deuterium substituted C 1-4Alkoxy, -SF5, -C(O)OR 14 、-C(O)R 15 、-OC(O)R 15 、-NR 16 R 17 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 ;

[0058] Each R3 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -SF5, -OR 14 and -NR 16 R 17 ;

[0059] Each R4 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -SF5, -OR 14 and -NR 16 R 17 ;

[0060] Each R5 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -SF5, -OR 14 and -NR 16 R 17 ;

[0061] Each R 6a and each R 7a are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C6-8 Aryl, 5-8 membered heteroaryl, -SF5, -S(O)(=NR 10 )R 11 、-N=S(O)R 11 R 12 、-N=SR 11 R 12 、-OS(O)2R 13 、-S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)SR 14 、-SC(O)R 15 、-C(O)R 15 、-OC(O)R 15 、-P(O)(R 15 )2、-NR 16 R 17 、-C(=NR 16 )R 15 、-N(R 16 )-C(=NR 17 )R 15 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -S(O)(=NR 10 )R 11 、-N=S(O)R 11 R 12 、-N=SR 11 R 12 、-OS(O)2R 13 、-S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)SR 14 、-SC(O)R 15 、-C(O)R 15 、-OC(O)R 15 、-P(O)(R 15 )2、-NR 16 R17 、-C(=NR 16 )R 15 、-N(R 16 )-C(=NR 17 )R 15 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 The above groups are independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -S(O)(=NR 10 )R 11 、-N=S(O)R 11 R 12 、-N=SR 11 R 12 、-OS(O)2R 13 、-S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)SR 14 、-SC(O)R 15 、-C(O)R 15 、-OC(O)R 15 、-P(O)(R 15 )2、-NR 16 R 17 、-C(=NR 16 )R 15 、-N(R 16 )-C(=NR 17 )R 15 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 substituted by a substituent;

[0062] Each R 6b and each R 7b are each independently selected from hydrogen, deuterium, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -S(O)(=NR 10 )R 11 、-S(O) r R 13 、-C(O)OR 14 、-C(O)SR 14 、-C(O)R 15 、-P(O)(R 15 )2、-C(=NR 16 )R 15 and -C(O)NR 16 R 17 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -S(O)(=NR 10 )R 11 、-N=S(O)R 11 R 12 、-N=SR 11 R 12 、-OS(O)2R 13 、-S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)SR 14 、-SC(O)R 15 、-C(O)R 15 、-OC(O)R 15 、-P(O)(R 15 )2、-NR 16 R 17 、-C(=NR 16 )R 15 、-N(R 16 )-C(=NR 17 )R 15 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 substituted by a substituent;

[0063] Alternatively, in the compound of formula (IIa1) or the compound of formula (IIa3), R 6b and R 7a Together with the part directly connected thereto, a 3-8 membered heterocyclic group or a 5-8 membered heteroaryl group is formed, wherein the above 3-8 membered heterocyclic group or the 5-8 membered heteroaryl group is independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, =O, =S, -SF5, -S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)R 15 、-OC(O)R 15 and -NR 16 R 17 substituted by a substituent;

[0064] Alternatively, in the compound of formula (IIa2) or the compound of formula (IIa4), R 6a and R 7b Together with the part directly connected thereto, a 3-8 membered heterocyclic group or a 5-8 membered heteroaryl group is formed, wherein the above 3-8 membered heterocyclic group or the 5-8 membered heteroaryl group is independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, =O, =S, -SF5, -S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)R 15 、-OC(O)R 15 and -NR 16 R 17 substituted by a substituent;

[0065] Each R 8a and R 9a are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C6-8 Aryl, 5-8 membered heteroaryl, -SF5, -S(O)(=NR 10 )R 11 、-N=S(O)R 11 R 12 、-N=SR 11 R 12 、-OS(O)2R 13 、-S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)SR 14 、-SC(O)R 15 、-C(O)R 15 、-OC(O)R 15 、-P(O)(R 15 )2、-NR 16 R 17 、-C(=NR 16 )R 15 、 -N(R 16 )-C(=NR 17 )R 15 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -S(O)(=NR 10 )R 11 、-N=S(O)R 11 R 12 、-N=SR 11 R 12 、-OS(O)2R 13 、-S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)SR 14 、-SC(O)R 15 、-C(O)R 15 、-OC(O)R 15、-P(O)(R 15 )2、-NR 16 R 17 、-C(=NR 16 )R 15 、-N(R 16 )-C(=NR 17 )R 15 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 substituted by a substituent;

[0066] Among them, R 10 、R 11 、R 12 、R 13 、R 14 、R 15 、R 16 、R 17 , m and r are as described for the compound of formula (I).

[0067] As a further preferred embodiment, among the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, the compound of formula (I) is the following formula (IIIa1), formula (IIIa2), formula (IIIa3) or formula (IIIa4):

[0068] wherein each X1 is independently CR4 or N;

[0069] Each W is independently N or CR 8a ;

[0070] Each Q is independently N or CR 9a ;

[0071] Each U is independently NR 1a , CR 1b R 1c , O or S;

[0072] Each p is independently 1, 2 or 3; each q is independently 0, 1, 2 or 3;

[0073] Each R1 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -SF5, -S(O)(=NR 10 )R 11 、-N=S(O)R 11 R12 、-S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)R 15 、-NR 16 R 17 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, =O, =S, -SF5, -S(O)(=NR 10 )R 11 、-N=S(O)R 11 R 12 、-S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)R 15 、-NR 16 R 17 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 substituted by a substituent;

[0074] Each R 1a are each independently selected from hydrogen, deuterium, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -S(O)(=NR 10 )R 11 、-S(O) r R 13 、-C(O)OR 14 、-C(O)R 15 and -C(O)NR 16 R 17 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, =O, =S, -SF5, -S(O)(=NR 10 )R 11 、-N=S(O)R 11 R 12 、-S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)R 15 、-NR 16 R 17 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 substituted by a substituent;

[0075] Each R 1b and R 1c are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -SF5, -S(O)(=NR 10 )R 11 、-N=S(O)R 11 R 12 、-S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)R 15 、-NR 16 R 17 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, =O, =S, -SF5, -S(O)(=NR 10 )R 11 、-N=S(O)R11 R 12 、-S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)R 15 、-NR 16 R 17 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 substituted by a substituent;

[0076] Each R2 is independently selected from halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 1-4 Alkoxy, halogen substituted C 1-4 Alkoxy, deuterium substituted C 1-4 Alkoxy, -NR 16 R 17 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 ;

[0077] Each R4 is independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, n-propoxy, isopropoxy, trifluoromethyl, trideuteriomethyl, trifluoromethoxy, trideuteriomethoxy, vinyl, ethynyl, cyclopropyl, cyclobutyl, cyclopropyloxy, cyclobutyloxy, oxetanyl, azetidinyl, -SF5, hydroxyl, amino, methylamino and dimethylamino;

[0078] Each R5 is independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, n-propoxy, isopropoxy, trifluoromethyl, trideuteriomethyl, trifluoromethoxy, trideuteriomethoxy, vinyl, ethynyl, cyclopropyl, cyclobutyl, cyclopropyloxy, cyclobutyloxy, oxetanyl, azetidinyl, -SF5, hydroxyl, amino, methylamino and dimethylamino;

[0079] Each R 6a and each R 7a are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -SF5, -S(O) r R13 、-OR 14 、-C(O)OR 14 、-C(O)R 15 、-OC(O)R 15 、-NR 16 R 17 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, =O, =S, -SF5, -S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)R 15 、-OC(O)R 15 、-NR 16 R 17 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 The above groups are independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, =O, =S, -SF5, -S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)R 15 、-OC(O)R 15 、-NR 16 R 17 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 substituted by a substituent;

[0080] Each R 6b and each R 7b are each independently selected from hydrogen, deuterium, C1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -S(O) r R 13 、-C(O)OR 14 、-C(O)R 15 and -C(O)NR 16 R 17 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, =O, =S, -SF5, -S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)R 15 、-OC(O)R 15 、-NR 16 R 17 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 substituted by a substituent;

[0081] Alternatively, in the compound of formula (IIIa1) or the compound of formula (IIIa3), R 6b and R 7a Together with the part directly connected thereto, a 3-8 membered heterocyclic group or a 5-8 membered heteroaryl group is formed, wherein the above 3-8 membered heterocyclic group or the 5-8 membered heteroaryl group is independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, =O, =S, -SF5, -S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)R 15 、-OC(O)R 15 and -NR 16 R 17substituted by a substituent;

[0082] Alternatively, in the compound of formula (IIIa2) or the compound of formula (IIIa4), R 6a and R 7b Together with the part directly connected thereto, a 3-8 membered heterocyclic group or a 5-8 membered heteroaryl group is formed, wherein the above 3-8 membered heterocyclic group or the 5-8 membered heteroaryl group is independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, =O, =S, -SF5, -S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)R 15 、-OC(O)R 15 and -NR 16 R 17 substituted by a substituent;

[0083] Each R 8a and R 9a are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -SF5, -S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)R 15 、-OC(O)R 15 、-NR 16 R 17 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, =O, =S, -SF5, -S(O) r R13 、-OR 14 、-C(O)OR 14 、-C(O)R 15 、-OC(O)R 15 、-NR 16 R 17 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 substituted by a substituent;

[0084] Among them, R 10 、R 11 、R 12 、R 13 、R 14 、R 15 、R 16 、R 17 , m and r are as described for the compound of formula (I).

[0085] As a further preferred embodiment, among the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, the compound of formula (I) is the following formula (IVa1), formula (IVa2), formula (IVa3) or formula (IVa4):

[0086] wherein each X1 is independently CH or N;

[0087] Each U is independently NR 1a , CH2, O or S; each p is independently 1 or 2;

[0088] Each R 1a are each independently selected from hydrogen, deuterium, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, methylsulfinyl, methylsulfonyl, isopropylsulfonyl, cyclopropylsulfonyl, aminosulfonyl and C 1-4 Alkanoyl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, hydroxyl, carboxyl, C 1-4 Alkyl, C 1-4 Alkoxy, halogen substituted C 1-4 Alkyl, halogen substituted C 1-4 Alkoxy, deuterium substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyloxy, =O, =S, -NR 16 R 17and -C(O)NR 16 R 17 substituted by a substituent;

[0089] Each R2 is independently selected from halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 1-4 Alkoxy, halogen substituted C 1-4 Alkoxy, deuterium substituted C 1-4 Alkoxy, -NR 16 R 17 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 ;

[0090] Each R5 is independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, methoxy, trifluoromethyl, trifluoromethoxy, trifluoroethoxy, trideuteriomethyl, trideuteriomethoxy, cyclopropyl, cyclopropyloxy, hydroxy, amino, methylamino, and dimethylamino;

[0091] Each R 6a and each R 7a are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, methylsulfinyl, methylsulfonyl, isopropylsulfonyl, cyclopropylsulfonyl, aminosulfonyl, amino, methylamino, dimethylamino, C 1-4 Alkanoyl and -C(O)NR 16 R 17 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, hydroxyl, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyloxy, =O, =S, -NR 16 R 17 and -C(O)NR 16 R 17 The above groups are independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, hydroxyl, C 1-4 Alkyl, C 1-4 Alkoxy, halogen substituted C 1-4 Alkyl, halogen substituted C 1-4 Alkoxy, deuterium substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkoxy, C 3-6 Cycloalkyl, C3-6 Cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyloxy, =O, =S, -NR 16 R 17 and -C(O)NR 16 R 17 substituted by a substituent;

[0092] Each R 6b and each R 7b are each independently selected from hydrogen, deuterium, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, methylsulfinyl, methylsulfonyl, isopropylsulfonyl, cyclopropylsulfonyl, aminosulfonyl and C 1-4 Alkanoyl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, hydroxyl, C 1-4 Alkyl, C 1-4 Alkoxy, halogen substituted C 1-4 Alkyl, halogen substituted C 1-4 Alkoxy, deuterium substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyloxy, =O, =S, -NR 16 R 17 and -C(O)NR 16 R 17 substituted by a substituent;

[0093] Alternatively, in the compound of formula (IVa1) or the compound of formula (IVa3), R 6b and R 7a Together with the part directly connected thereto, a 3-8 membered heterocyclic group or a 5-8 membered heteroaryl group is formed, wherein the above 3-8 membered heterocyclic group or the 5-8 membered heteroaryl group is independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, hydroxyl, C 1-4 Alkyl, C 1-4 Alkoxy, halogen substituted C 1-4 Alkyl, halogen substituted C 1-4 Alkoxy, deuterium substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyloxy, =O, =S and -NR 16 R 17 substituted by a substituent;

[0094] Alternatively, in the compound of formula (IVa2) or the compound of formula (IVa4), R 6a and R7b Together with the part directly connected thereto, a 3-8 membered heterocyclic group or a 5-8 membered heteroaryl group is formed, wherein the above 3-8 membered heterocyclic group or the 5-8 membered heteroaryl group is independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, hydroxyl, C 1-4 Alkyl, C 1-4 Alkoxy, halogen substituted C 1-4 Alkyl, halogen substituted C 1-4 Alkoxy, deuterium substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyloxy, =O, =S and -NR 16 R 17 substituted by a substituent;

[0095] Among them, R 13 、R 14 、R 15 、R 16 and R 17 As described for the compound of formula (I).

[0096] As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, each U is independently NR 1a , CH2, O or S;

[0097] Each R 1a are each independently selected from hydrogen, deuterium, C 1-4 Alkyl, C 3-6 Cycloalkyl, methylsulfonyl and isopropylsulfonyl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 The alkyl group may be substituted by cycloalkyl, -C(O)NH2, -C(O)NHCH3 and -C(O)N(CH3)2.

[0098] As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, each R5 is independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, methoxy, trifluoromethyl, trifluoromethoxy, trifluoroethoxy, trideuteriomethyl, trideuteriomethoxy and cyclopropyl.

[0099] As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, R 6b Selected from hydrogen, deuterium, C 1-4 Alkyl, C 3-6Cycloalkyl, 3-6 membered heterocyclic group, methylsulfonyl and C 1-4 Alkanoyl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, hydroxyl, C 1-4 Alkyl, C 1-4 Alkoxy, halogen substituted C 1-4 Alkyl, halogen substituted C 1-4 Alkoxy, deuterium substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyl and -NR 16 R 17 substituted by a substituent;

[0100] R 7a Selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, methylsulfonyl, amino, methylamino, dimethylamino, C 1-4 Alkanoyl and -C(O)NR 16 R 17 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, hydroxyl, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyl and -NR 16 R 17 The above groups are independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, hydroxyl, C 1-4 Alkyl, C 1-4 Alkoxy, halogen substituted C 1-4 Alkyl, halogen substituted C 1-4 Alkoxy, deuterium substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyl and -NR 16 R 17 substituted by a substituent;

[0101] Or, R 6b and R 7a Together with the part directly connected thereto, a 3-8 membered heterocyclic group is formed, wherein the above 3-8 membered heterocyclic group is optionally further substituted by one or more selected from deuterium, halogen, cyano, hydroxyl, C 1-4 Alkyl, C 1-4 Alkoxy, halogen substituted C1-4 Alkyl, halogen substituted C 1-4 Alkoxy, deuterium substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyl and -NR 16 R 17 substituted by a substituent;

[0102] Among them, R 16 and R 17 As described for the compound of formula (I).

[0103] As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, R 6a Selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, methylsulfonyl, amino, methylamino, dimethylamino, C 1-4 Alkanoyl and -C(O)NR 16 R 17 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, hydroxyl, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyl and -NR 16 R 17 The above groups are independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, hydroxyl, C 1-4 Alkyl, C 1-4 Alkoxy, halogen substituted C 1-4 Alkyl, halogen substituted C 1-4 Alkoxy, deuterium substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyl and -NR 16 R 17 substituted by a substituent;

[0104] R 7b Selected from hydrogen, deuterium, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, methylsulfonyl and C 1-4 Alkanoyl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, hydroxyl, C 1-4Alkyl, C 1-4 Alkoxy, halogen substituted C 1-4 Alkyl, halogen substituted C 1-4 Alkoxy, deuterium substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyl and -NR 16 R 17 substituted by a substituent;

[0105] Or, R 6a and R 7b Together with the part directly connected thereto, a 3-8 membered heterocyclic group is formed, wherein the above 3-8 membered heterocyclic group is optionally further substituted by one or more selected from deuterium, halogen, cyano, hydroxyl, C 1-4 Alkyl, C 1-4 Alkoxy, halogen substituted C 1-4 Alkyl, halogen substituted C 1-4 Alkoxy, deuterium substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyl and -NR 16 R 17 substituted by a substituent;

[0106] Among them, R 16 and R 17 As described for the compound of formula (I).

[0107] As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, each R 16 and R 17 are independently selected from hydrogen, deuterium, hydroxyl, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, sulfinyl, sulfonyl, methylsulfonyl, isopropylsulfonyl, cyclopropylsulfonyl, p-toluenesulfonyl, aminosulfonyl, dimethylaminosulfonyl and C 1-4 Alkanoyl;

[0108] Or, R 16 and R 17Together with the nitrogen atom directly connected thereto, a 4-6 membered heterocyclic group is formed, wherein the 4-6 membered heterocyclic group is optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 The cycloalkyl group and the 3- to 6-membered heterocyclic group are substituted.

[0109] As a preferred embodiment, among the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, the compound of formula (I) is a compound of formula (IIb1) or formula (IIb2):

[0110] wherein each X1 is independently CR4 or N;

[0111] Each W is independently N or CR 8a ;

[0112] Each Q is independently N or CR 9a ;

[0113] Each ring A is independently phenyl or a 5-6 membered heteroaryl group;

[0114] Each R1 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-8 membered heterocyclic group, C 3-6 Cycloalkyl substituted C 1-4 Alkyl, 3-6 membered heterocyclic substituted C 1-4 Alkyl, -SF5, -S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)R 15 、-OC(O)R 15 、-NR 16 R 17 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, =O, =S, -SF5, -S(O) r R13 、-OR 14 、-C(O)OR 14 、-C(O)R 15 、-OC(O)R 15 、-NR 16 R 17 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 The above groups are independently substituted with one or more substituents selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)R 15 、-OC(O)R 15 、-NR 16 R 17 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 substituted by a substituent;

[0115] Each R4 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -SF5, -OR 14 and -NR 16 R 17 ;

[0116] Each R5 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6Cycloalkyl, 3-6 membered heterocyclic group, -SF5, -OR 14 and -NR 16 R 17 ;

[0117] R 6a and R 7a are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -SF5, -S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)R 15 、-OC(O)R 15 、-NR 16 R 17 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, =O, =S, -SF5, -S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)R 15 、-OC(O)R 15 、-NR 16 R 17 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 The above groups are independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, =O, =S, -SF5, -S(O) r R 13 、-OR 14 、-C(O)OR14 、-C(O)R 15 、-OC(O)R 15 、-NR 16 R 17 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 substituted by a substituent;

[0118] R 6b and R 7b are each independently selected from hydrogen, deuterium, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -S(O) r R 13 、-C(O)OR 14 、-C(O)R 15 and -C(O)NR 16 R 17 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, =O, =S, -SF5, -S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)R 15 、-OC(O)R 15 、-NR 16 R 17 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 substituted by a substituent;

[0119] Alternatively, in the compound of formula (IIb1), R 6b and R 7a Together with the part directly connected thereto, a 3-8 membered heterocyclic group or a 5-8 membered heteroaryl group is formed, wherein the above 3-8 membered heterocyclic group or the 5-8 membered heteroaryl group is independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, =O, =S, -SF5, -S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)R 15 、-OC(O)R 15 and -NR 16 R 17 substituted by a substituent;

[0120] Alternatively, in the compound of formula (IIb2), R 6a and R 7b Together with the part directly connected thereto, a 3-8 membered heterocyclic group or a 5-8 membered heteroaryl group is formed, wherein the above 3-8 membered heterocyclic group or the 5-8 membered heteroaryl group is independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, =O, =S, -SF5, -S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)R 15 、-OC(O)R 15 and -NR 16 R 17 substituted by a substituent;

[0121] Each R 8a and R 9a are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -SF5, -S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)R 15 、-OC(O)R 15 、-NR 16 R 17 、-C(O)NR 16 R 17 and -N(R16 )-C(O)R 15 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, =O, =S, -SF5, -S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)R 15 、-OC(O)R 15 、-NR 16 R 17 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 substituted by a substituent;

[0122] Among them, R 13 、R 14 、R 15 、R 16 、R 17 , m and r are as described for the compound of formula (I).

[0123] As a further preferred embodiment, among the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, the compound of formula (I) is a compound of formula (IIIb1) or formula (IIIb2):

[0124] wherein each X1 is independently CH or N;

[0125] Ring A is selected from phenyl, pyridyl, pyrimidinyl, pyridazinyl, triazinyl, furanyl, thienyl, imidazolyl, triazolyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl and isothiazolyl;

[0126] Each R1 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-8 membered heterocyclic group, C 3-6 Cycloalkyl substituted C 1-4 Alkyl, 3-6 membered heterocyclic substituted C 1-4 Alkyl, -C(O)R 15 、-NR 16 R17 , and -C(O)NR 16 R 17 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, hydroxy substituted C 1-4 Alkyl, cyano substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, =O, =S, -SF5, -S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)R 15 、-OC(O)R 15 、-NR 16 R 17 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 substituted by a substituent;

[0127] Each R5 is independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, methoxy, trifluoromethyl, trifluoromethoxy, trifluoroethoxy, trideuteriomethyl, trideuteriomethoxy, cyclopropyl, cyclopropyloxy, hydroxy, amino, methylamino, and dimethylamino;

[0128] Among them, R 6a 、R 6b 、R 7a 、R 7b 、R 13 、R 14 、R 15 、R 16 、R 17 , m and r are as described for the compound of formula (I).

[0129] As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, R 6b Selected from hydrogen, deuterium, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, methylsulfinyl, methylsulfonyl, isopropylsulfonyl, cyclopropylsulfonyl, aminosulfonyl and C 1-4 Alkanoyl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, hydroxyl, C 1-4 Alkyl, C 1-4Alkoxy, halogen substituted C 1-4 Alkyl, halogen substituted C 1-4 Alkoxy, deuterium substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyloxy, =O, =S, -NR 16 R 17 and -C(O)NR 16 R 17 substituted by a substituent;

[0130] R 7a Selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, methylsulfinyl, methylsulfonyl, isopropylsulfonyl, cyclopropylsulfonyl, aminosulfonyl, amino, methylamino, dimethylamino, C 1-4 Alkanoyl and -C(O)NR 16 R 17 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, hydroxyl, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyloxy, =O, =S, -NR 16 R 17 and -C(O)NR 16 R 17 The above groups are independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, hydroxyl, C 1-4 Alkyl, C 1-4 Alkoxy, halogen substituted C 1-4 Alkyl, halogen substituted C 1-4 Alkoxy, deuterium substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyloxy, =O, =S, -NR 16 R 17 and -C(O)NR 16 R 17 substituted by a substituent;

[0131] Or, R 6b and R 7aTogether with the part directly connected thereto, a 3-8 membered heterocyclic group is formed, wherein the above 3-8 membered heterocyclic group is independently optionally further substituted with one or more selected from deuterium, halogen, cyano, hydroxyl, C 1-4 Alkyl, C 1-4 Alkoxy, halogen substituted C 1-4 Alkyl, halogen substituted C 1-4 Alkoxy, deuterium substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyloxy, =O, =S and -NR 16 R 17 substituted by a substituent;

[0132] Among them, R 16 and R 17 As described for the compound of formula (I).

[0133] As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, R 6a Selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, methylsulfinyl, methylsulfonyl, isopropylsulfonyl, cyclopropylsulfonyl, aminosulfonyl, amino, methylamino, dimethylamino, C 1-4 Alkanoyl and -C(O)NR 16 R 17 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, hydroxyl, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyloxy, =O, =S, -NR 16 R 17 and -C(O)NR 16 R 17 The above groups are independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, hydroxyl, C 1-4 Alkyl, C 1-4 Alkoxy, halogen substituted C 1-4 Alkyl, halogen substituted C 1-4 Alkoxy, deuterium substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyloxy, =O, =S, -NR 16R 17 and -C(O)NR 16 R 17 substituted by a substituent;

[0134] R 7b Selected from hydrogen, deuterium, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, methylsulfinyl, methylsulfonyl, isopropylsulfonyl, cyclopropylsulfonyl, aminosulfonyl and C 1-4 Alkanoyl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, hydroxyl, C 1-4 Alkyl, C 1-4 Alkoxy, halogen substituted C 1-4 Alkyl, halogen substituted C 1-4 Alkoxy, deuterium substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyloxy, =O, =S, -NR 16 R 17 and -C(O)NR 16 R 17 substituted by a substituent;

[0135] Or, R 6a and R 7b Together with the part directly connected thereto, a 3-8 membered heterocyclic group is formed, wherein the above 3-8 membered heterocyclic group is independently optionally further substituted with one or more selected from deuterium, halogen, cyano, hydroxyl, C 1-4 Alkyl, C 1-4 Alkoxy, halogen substituted C 1-4 Alkyl, halogen substituted C 1-4 Alkoxy, deuterium substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyloxy, =O, =S and -NR 16 R 17 substituted by a substituent;

[0136] Among them, R 16 and R 17 As described for the compound of formula (I).

[0137] As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, each R 13 independently selected from hydrogen, deuterium, hydroxyl, C 1-4 Alkyl, 3-6 membered heterocyclic group and -NR16 R 17 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, hydroxyl, =O, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyl and -NR 16 R 17 substituted by a substituent;

[0138] Each R 14 independently selected from hydrogen, deuterium, C 1-4 Alkyl and 3-6 membered heterocyclic groups, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, cyano, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyl and -NR 16 R 17 substituted by a substituent;

[0139] Each R 15 independently selected from hydrogen, deuterium, hydroxyl, C 1-4 Alkyl, C 1-4 Alkoxy, C 2-4 Alkenyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyl and -NR 16 R 17 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, cyano, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyl and -NR 16 R 17 substituted by a substituent;

[0140] Among them, R 16 and R 17 As described for the compound of formula (I).

[0141] As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, each R 16 and R 17 are independently selected from hydrogen, deuterium, hydroxyl, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, sulfinyl, sulfonyl, methylsulfonyl, isopropylsulfonyl, cyclopropylsulfonyl, p-toluenesulfonyl, aminosulfonyl, dimethylaminosulfonyl and C 1-4 Alkanoyl;

[0142] Or, R 16 and R 17 Together with the nitrogen atom directly connected thereto, a 4-6 membered heterocyclic group is formed, wherein the 4-6 membered heterocyclic group is optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 The cycloalkyl group and the 3- to 6-membered heterocyclic group are substituted.

[0143] As the most preferred embodiment, the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof include but are not limited to the following compounds:

[0144] In a second aspect, the present invention provides a pharmaceutical composition comprising a compound of formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

[0145] The present invention also relates to the use of the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof in the preparation of drugs for treating at least some tumors associated with CDK.

[0146] As a preferred embodiment, the present invention also relates to the use of the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof in the preparation of a drug for treating at least some tumors associated with CDK, wherein the tumor is cancer.

[0147] The present invention also relates to the use of a compound of formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating breast cancer, malignant brain tumor, colon cancer, small cell lung cancer, non-small cell lung cancer, bladder cancer, ovarian cancer, prostate cancer, chronic lymphocytic leukemia, lymphoma, myeloma, acute myeloid leukemia, secondary pancreatic cancer or secondary brain metastasis that is at least partially associated with CDK.

[0148] The present invention also relates to the use of the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof for treating at least some tumors associated with CDK.

[0149] As a preferred embodiment, the present invention also relates to the use of the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof for treating at least some tumors associated with CDK.

[0150] The present invention also relates to a compound of formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof for use in treating breast cancer, malignant brain tumors, colon cancer, small cell lung cancer, non-small cell lung cancer, bladder cancer, ovarian cancer, prostate cancer, chronic lymphocytic leukemia, lymphoma, myeloma, acute myeloid leukemia, secondary pancreatic cancer or secondary brain metastasis that is at least partially associated with CDK. DETAILED DESCRIPTION

[0151] After extensive and in-depth research, the inventors of this application have developed, for the first time, a CDK inhibitor having the structure of Formula (I) below. This series of compounds can be widely used in the preparation of drugs for treating at least some CDK-related cancers and tumors, and is expected to be developed into a new generation of CDK inhibitors. This has led to the completion of the present invention.

[0152] Detailed Description: Unless otherwise stated or specifically indicated, the following terms used in the specification and claims have the following meanings.

[0153] "Alkyl" refers to a straight-chain or branched saturated aliphatic hydrocarbon group, preferably a straight-chain alkyl group and a branched alkyl group having 1 to 10, 1 to 6, or 1 to 4 carbon atoms, including but not limited to methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl , 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, n-heptyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, 2,3-dimethylpentyl, 2,4-dimethylpentyl, 2,2-dimethylpentyl, 3,3-dimethylpentyl, 2-ethylpentyl, 3-ethylpentyl, n-octyl, 2,3-dimethylhexyl, 2,4-dimethylhexyl, 2,5-dimethylhexyl, 2,2-dimethylhexyl, 3,3-dimethylhexyl, 4,4-dimethylhexyl, 2-ethylhexyl, 3-ethylhexyl, 4-ethylhexyl, 2-methyl-2-ethylpentyl, 2-methyl-3-ethylpentyl or its various branched chain isomers, etc. “C 1-10 "Alkyl" refers to a straight chain alkyl group or a branched chain alkyl group containing 1 to 10 carbon atoms. 1-4 "Alkyl" refers to straight chain alkyl and branched chain alkyl groups containing 1 to 4 carbon atoms, "C 0-8 "Alkyl" refers to straight chain alkyl and branched chain alkyl groups including 0 to 8 carbon atoms, "C 0-4 The term "alkyl" refers to straight-chain and branched-chain alkyl groups having 0 to 4 carbon atoms.

[0154] The alkyl group may be optionally substituted or unsubstituted. When substituted, the substituents are preferably one or more (preferably 1, 2, 3 or 4) of the following groups independently selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=NR 10 )R 11 、-C 0-8 Alkyl-N=S(O)R 11 R 12、-C 0-8 Alkyl-N=SR 11 R 12 、-C 0-8 Alkyl-OS(O)2R 13 、-C 0-8 Alkyl-S(O) r R 13 、-C 0-8 Alkyl-OR 14 、-C 0-8 Alkyl-C(O)OR 14 、-C 0-8 Alkyl-C(O)SR 14 、-C 0-8 Alkyl-SC(O)R 15 、-C 0-8 Alkyl-C(O)R 15 、-C 0-8 Alkyl-OC(O)R 15 、-C 0-8 Alkyl-P(O)(R 15 )2. -C 0-8 Alkyl-NR 16 R 17 、-C 0-8 Alkyl-C(=NR 16 )R 15 、-C 0-8 Alkyl-N(R 16 )-C(=NR 17 )R 15 、-C 0-8 Alkyl-C(O)NR 16 R 17 and -C 0-8 Alkyl-N(R 16 )-C(O)R 15 substituted by a substituent.

[0155] "Cycloalkyl" or "carbocycle" refers to a saturated or partially unsaturated monocyclic or polycyclic aliphatic hydrocarbon substituent. The partially unsaturated cyclic hydrocarbon refers to a cyclic hydrocarbon that may contain one or more (preferably 1, 2 or 3) double bonds, but no ring has a completely conjugated π electron system. Cycloalkyl is divided into monocyclic cycloalkyl and polycyclic cycloalkyl, preferably including 3 to 12 or 3 to 8 or 3 to 6 carbon atoms. For example, "C 3-12 "Cycloalkyl" refers to a cycloalkyl group comprising 3 to 12 carbon atoms, "C 4-8 "Cycloalkyl" refers to a cycloalkyl group comprising 4 to 8 carbon atoms, "C 3-8 "Cycloalkyl" refers to a cycloalkyl group comprising 3 to 8 carbon atoms, "C 3-6 "Cycloalkyl" refers to a cycloalkyl group comprising 3 to 6 carbon atoms, wherein:

[0156] Monocyclic cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptatrienyl, cyclooctyl, and the like.

[0157] Polycyclic cycloalkyl groups include spiro, fused, and bridged cycloalkyl groups. "Spiroalkyl" refers to a polycyclic group in which the rings share a carbon atom (called a spiro atom). These may contain one or more (preferably 1, 2, or 3) double bonds, but no ring has a completely conjugated π electron system. Spiroalkyl groups are classified as monospiroalkyl, bispiroalkyl, or polyspiroalkyl groups based on the number of spiro atoms shared between the rings. Spiroalkyl groups include, but are not limited to:

[0158] "Fused cycloalkyl" refers to an all-carbon polycyclic group in which each ring shares a pair of adjacent carbon atoms with other rings in the system, wherein one or more rings may contain one or more (preferably 1, 2, or 3) double bonds, but no ring has a completely conjugated π electron system. Depending on the number of constituent rings, fused cycloalkyl groups can be classified as bicyclic, tricyclic, tetracyclic, or polycyclic. Fused cycloalkyl groups include, but are not limited to:

[0159] "Bridged cycloalkyl" refers to an all-carbon polycyclic group in which any two rings share two carbon atoms that are not directly connected. These may contain one or more (preferably 1, 2, or 3) double bonds, but no ring has a completely conjugated π electron system. Depending on the number of constituent rings, bridged cycloalkyl groups can be classified as bicyclic, tricyclic, tetracyclic, or polycyclic. Bridged cycloalkyl groups include, but are not limited to:

[0160] The cycloalkyl ring may be fused to an aryl, heteroaryl or heterocycloalkyl ring, wherein the ring connected to the parent structure is a cycloalkyl, including but not limited to indanyl, tetrahydronaphthyl, benzocycloheptanyl and the like.

[0161] Cycloalkyl may be optionally substituted or unsubstituted. When substituted, the substituents are preferably one or more (preferably 1, 2, 3 or 4) of the following groups independently selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=NR 10 )R11 、-C 0-8 Alkyl-N=S(O)R 11 R 12 、-C 0-8 Alkyl-N=SR 11 R 12 、-C 0-8 Alkyl-OS(O)2R 13 、-C 0-8 Alkyl-S(O) r R 13 、-C 0-8 Alkyl-OR 14 、-C 0-8 Alkyl-C(O)OR 14 、-C 0-8 Alkyl-C(O)SR 14 、-C 0-8 Alkyl-SC(O)R 15 、-C 0-8 Alkyl-C(O)R 15 、-C 0-8 Alkyl-OC(O)R 15 、-C 0-8 Alkyl-P(O)(R 15 )2. -C 0-8 Alkyl-NR 16 R 17 、-C 0-8 Alkyl-C(=NR 16 )R 15 、-C 0-8 Alkyl-N(R 16 )-C(=NR 17 )R 15 、-C 0-8 Alkyl-C(O)NR 16 R 17 and -C 0-8 Alkyl-N(R 16 )-C(O)R 15 substituted by a substituent.

[0162] "Heterocyclyl" or "heterocycle" refers to a saturated or partially unsaturated monocyclic or polycyclic aliphatic hydrocarbon substituent, wherein the partially unsaturated cyclic hydrocarbon refers to a cyclic hydrocarbon that may contain one or more (preferably 1, 2 or 3) double bonds, but no ring has a completely conjugated π electron system, and one or more (preferably 1, 2, 3 or 4) ring atoms in the heterocyclyl are selected from N, O, N·O or S(O) r(wherein r is an integer of 0, 1, or 2), but excluding the ring portion of -OO-, -OS-, or -SS-, the remaining ring atoms are carbon. Preferably, the heterocyclyl group comprises 3 to 12, 3 to 8, or 3 to 6 ring atoms, for example, "3-6 membered heterocyclyl" refers to a heterocyclyl group comprising 3 to 6 ring atoms, "3-8 membered heterocyclyl" refers to a heterocyclyl group comprising 3 to 8 ring atoms, "4-8 membered heterocyclyl" refers to a heterocyclyl group comprising 4 to 8 ring atoms, "4-10 membered heterocyclyl" refers to a heterocyclyl group comprising 4 to 10 ring atoms, "5-8 membered heterocyclyl" refers to a heterocyclyl group comprising 5 to 8 ring atoms, and "3-12 membered heterocyclyl" refers to a heterocyclyl group comprising 3 to 12 ring atoms.

[0163] Monocyclic heterocyclyl groups include, but are not limited to, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, homopiperazinyl, oxetanyl, tetrahydrofuranyl, and the like.

[0164] Polycyclic heterocyclic groups include spiro, fused and bridged heterocyclic groups. "Spiro heterocyclic group" refers to a polycyclic heterocyclic group in which the single rings share an atom (called a spiro atom), wherein one or more (preferably 1, 2, 3 or 4) ring atoms are selected from N, O, N·O or S(O). r (where r is an integer 0, 1, or 2) with the remaining ring atoms being carbon. These may contain one or more double bonds (preferably 1, 2, or 3), but no ring has a completely conjugated π electron system. Spiro heterocyclic groups are classified as monospiro heterocyclic groups, dispiro heterocyclic groups, or polyspiro heterocyclic groups based on the number of spiro atoms shared between the rings. Spiro heterocyclic groups include, but are not limited to:

[0165] "Fused heterocyclyl" refers to a polycyclic heterocyclic group in which each ring in the system shares a pair of adjacent atoms with the other rings in the system, one or more (preferably 1, 2, 3 or 4) rings may contain one or more (preferably 1, 2 or 3) double bonds, but no ring has a completely conjugated π electron system, wherein one or more (preferably 1, 2, 3 or 4) ring atoms are selected from N, O, N·O or S(O) r (where r is an integer of 0, 1, or 2) and the remaining ring atoms are carbon. Depending on the number of rings, fused heterocyclic alkyl groups can be classified as bicyclic, tricyclic, tetracyclic, or polycyclic. Fused heterocyclic groups include, but are not limited to:

[0166] "Bridged heterocyclic group" refers to a polycyclic heterocyclic group in which any two rings share two atoms that are not directly connected, these may contain one or more (preferably 1, 2 or 3) double bonds, but no ring has a completely conjugated π electron system, wherein one or more (preferably 1, 2, 3 or 4) ring atoms are selected from N, O, N·O or S(O) r(where r is an integer of 0, 1, or 2) and the remaining ring atoms are carbon. Depending on the number of rings, bridged heterocyclic groups can be classified as bicyclic, tricyclic, tetracyclic, or polycyclic. Bridged heterocyclic groups include, but are not limited to:

[0167] The heterocyclyl ring may be fused to an aryl, heteroaryl or cycloalkyl ring, wherein the ring connected to the parent structure is a heterocyclyl, including but not limited to:

[0168] The heterocyclic group may be optionally substituted or unsubstituted. When substituted, the substituents are preferably one or more (preferably 1, 2, 3 or 4) of the following groups independently selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=NR 10 )R 11 、-C 0-8 Alkyl-N=S(O)R 11 R 12 、-C 0-8 Alkyl-N=SR 11 R 12 、-C 0-8 Alkyl-OS(O)2R 13 、-C 0-8 Alkyl-S(O) r R 13 、-C 0-8 Alkyl-OR 14 、-C 0-8 Alkyl-C(O)OR 14 、-C 0-8 Alkyl-C(O)SR 14 、-C 0-8 Alkyl-SC(O)R 15 、-C 0-8 Alkyl-C(O)R 15 、-C 0-8 Alkyl-OC(O)R 15 、-C 0-8 Alkyl-P(O)(R 15 )2. -C 0-8 Alkyl-NR 16 R 17、-C 0-8 Alkyl-C(=NR 16 )R 15 、-C 0-8 Alkyl-N(R 16 )-C(=NR 17 )R 15 、-C 0-8 Alkyl-C(O)NR 16 R 17 and -C 0-8 Alkyl-N(R 16 )-C(O)R 15 substituted by a substituent.

[0169] "Aryl" or "aromatic ring" refers to an all-carbon monocyclic or fused polycyclic (i.e., rings sharing adjacent pairs of carbon atoms) group, a polycyclic (i.e., rings with adjacent pairs of carbon atoms) group having a conjugated π electron system, preferably an all-carbon aromatic group containing 6-10 or 6-8 carbon atoms, for example, "C 6-10 "Aryl" refers to an all-carbon aromatic group containing 6-10 carbon atoms, including but not limited to phenyl and naphthyl. 6-8 "Aryl" refers to an all-carbon aromatic group containing 6-8 carbon atoms. The aromatic ring may be fused to a heteroaryl, heterocyclyl or cycloalkyl ring, wherein the ring connected to the parent structure is an aromatic ring, including but not limited to:

[0170] "Aryl" may be substituted or unsubstituted. When substituted, the substituents are preferably one or more (preferably 1, 2, 3 or 4) of the following groups independently selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=NR 10 )R 11 、-C 0-8 Alkyl-N=S(O)R 11 R 12 、-C 0-8 Alkyl-N=SR 11 R 12 、-C 0-8 Alkyl-OS(O)2R 13 、-C 0-8 Alkyl-S(O) r R13 、-C 0-8 Alkyl-OR 14 、-C 0-8 Alkyl-C(O)OR 14 、-C 0-8 Alkyl-C(O)SR 14 、-C 0-8 Alkyl-SC(O)R 15 、-C 0-8 Alkyl-C(O)R 15 、-C 0-8 Alkyl-OC(O)R 15 、-C 0-8 Alkyl-P(O)(R 15 )2. -C 0-8 Alkyl-NR 16 R 17 、-C 0-8 Alkyl-C(=NR 16 )R 15 、-C 0-8 Alkyl-N(R 16 )-C(=NR 17 )R 15 、-C 0-8 Alkyl-C(O)NR 16 R 17 and -C 0-8 Alkyl-N(R 16 )-C(O)R 15 substituted by a substituent.

[0171] "Heteroaryl" refers to a heteroaromatic system containing one or more (preferably 1, 2, 3 or 4) heteroatoms, including N, O, N·O and S(O)r (wherein r is an integer of 0, 1 or 2), preferably a heteroaromatic system containing 5-10, 5-8 or 5-6 ring atoms, for example, "5-8 membered heteroaryl" refers to a heteroaromatic system containing 5-8 ring atoms, and "5-10 membered heteroaryl" refers to a heteroaromatic system containing 5-10 ring atoms, including but not limited to furanyl, thienyl, pyridyl, pyrrolyl, N-alkylpyrrolyl, pyrimidinyl, pyrazinyl, imidazolyl, tetrazolyl, etc. The heteroaryl ring can be fused to an aryl, heterocyclyl or cycloalkyl ring, wherein the ring connected to the parent structure is a heteroaryl ring, including but not limited to:

[0172] "Heteroaryl" may be optionally substituted or unsubstituted. When substituted, the substituents are preferably one or more (preferably 1, 2, 3 or 4) of the following groups independently selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=NR 10 )R 11 、-C 0-8 Alkyl-N=S(O)R 11 R 12 、-C 0-8 Alkyl-N=SR 11 R 12 、-C 0-8 Alkyl-OS(O)2R 13 、-C 0-8 Alkyl-S(O) r R 13 、-C 0-8 Alkyl-OR 14 、-C 0-8 Alkyl-C(O)OR 14 、-C 0-8 Alkyl-C(O)SR 14 、-C 0-8 Alkyl-SC(O)R 15 、-C 0-8 Alkyl-C(O)R 15 、-C 0-8 Alkyl-OC(O)R 15 、-C 0-8 Alkyl-P(O)(R 15 )2. -C 0-8 Alkyl-NR 16 R 17 、-C 0-8 Alkyl-C(=NR 16 )R 15 、-C 0-8 Alkyl-N(R 16 )-C(=NR 17 )R 15 、-C 0-8 Alkyl-C(O)NR 16 R 17 and -C 0-8 Alkyl-N(R 16 )-C(O)R 15 substituted by a substituent.

[0173] "Alkenyl" refers to an alkyl group as defined above consisting of at least two carbon atoms and at least one carbon-carbon double bond, preferably a straight or branched alkenyl group containing 2-10 or 2-4 carbon atoms, for example, "C 2-10 "Alkenyl" refers to a straight or branched chain alkenyl containing 2 to 10 carbon atoms. 2-4 "Alkenyl" refers to a straight or branched chain alkenyl group containing 2 to 4 carbon atoms, including but not limited to ethenyl, 1-propenyl, 2-propenyl, 1-, 2- or 3-butenyl, etc.

[0174] "Alkenyl" may be substituted or unsubstituted. When substituted, the substituents are preferably one or more (preferably 1, 2, 3 or 4) of the following groups independently selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=NR 10 )R 11 、-C 0-8 Alkyl-N=S(O)R 11 R 12 、-C 0-8 Alkyl-N=SR 11 R 12 、-C 0-8 Alkyl-OS(O)2R 13 、-C 0-8 Alkyl-S(O) r R 13 、-C 0-8 Alkyl-OR 14 、-C 0-8 Alkyl-C(O)OR 14 、-C 0-8 Alkyl-C(O)SR 14 、-C 0-8 Alkyl-SC(O)R 15 、-C 0-8 Alkyl-C(O)R 15 、-C 0-8 Alkyl-OC(O)R 15 、-C 0-8 Alkyl-P(O)(R 15 )2. -C 0-8 Alkyl-NR 16 R17 、-C 0-8 Alkyl-C(=NR 16 )R 15 、-C 0-8 Alkyl-N(R 16 )-C(=NR 17 )R 15 、-C 0-8 Alkyl-C(O)NR 16 R 17 and -C 0-8 Alkyl-N(R 16 )-C(O)R 15 substituted by a substituent.

[0175] "Alkynyl" refers to an alkyl group as defined above consisting of at least two carbon atoms and at least one carbon-carbon triple bond, preferably a straight or branched chain alkynyl group containing 2-10 or 2-4 carbon atoms, for example, "C 2-10 "Alkynyl" refers to a straight or branched chain alkynyl containing 2 to 10 carbon atoms. 2-4 "Alkynyl" refers to a straight or branched chain alkynyl containing 2-4 carbon atoms, including but not limited to ethynyl, 1-propynyl, 2-propynyl, 1-, 2- or 3-butynyl, etc.

[0176] "Alkynyl" may be substituted or unsubstituted. When substituted, the substituents are preferably one or more (preferably 1, 2, 3 or 4) of the following groups independently selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=NR 10 )R 11 、-C 0-8 Alkyl-N=S(O)R 11 R 12 、-C 0-8 Alkyl-N=SR 11 R 12 、-C 0-8 Alkyl-OS(O)2R 13 、-C 0-8 Alkyl-S(O) r R 13 、-C 0-8 Alkyl-OR 14、-C 0-8 Alkyl-C(O)OR 14 、-C 0-8 Alkyl-C(O)SR 14 、-C 0-8 Alkyl-SC(O)R 15 、-C 0-8 Alkyl-C(O)R 15 、-C 0-8 Alkyl-OC(O)R 15 、-C 0-8 Alkyl-P(O)(R 15 )2. -C 0-8 Alkyl-NR 16 R 17 、-C 0-8 Alkyl-C(=NR 16 )R 15 、-C 0-8 Alkyl-N(R 16 )-C(=NR 17 )R 15 、-C 0-8 Alkyl-C(O)NR 16 R 17 and -C 0-8 Alkyl-N(R 16 )-C(O)R 15 substituted by a substituent.

[0177] "Alkoxy" refers to an -O-alkyl group, wherein alkyl is as defined above, for example, "C 1-10 "Alkoxy" refers to an alkyloxy group containing 1 to 10 carbon atoms. 1-4 "Alkoxy" refers to an alkyloxy group containing 1 to 4 carbon atoms. 1-2 The term "alkoxy" refers to an alkyloxy group containing 1 to 2 carbon atoms, including but not limited to methoxy, ethoxy, propoxy, butoxy, etc.

[0178] "Alkoxy" may be optionally substituted or unsubstituted. When substituted, the substituents are preferably one or more (preferably 1, 2, 3 or 4) of the following groups independently selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=NR 10)R 11 、-C 0-8 Alkyl-N=S(O)R 11 R 12 、-C 0-8 Alkyl-N=SR 11 R 12 、-C 0-8 Alkyl-OS(O)2R 13 、-C 0-8 Alkyl-S(O) r R 13 、-C 0-8 Alkyl-OR 14 、-C 0-8 Alkyl-C(O)OR 14 、-C 0-8 Alkyl-C(O)SR 14 、-C 0-8 Alkyl-SC(O)R 15 、-C 0-8 Alkyl-C(O)R 15 、-C 0-8 Alkyl-OC(O)R 15 、-C 0-8 Alkyl-P(O)(R 15 )2. -C 0-8 Alkyl-NR 16 R 17 、-C 0-8 Alkyl-C(=NR 16 )R 15 、-C 0-8 Alkyl-N(R 16 )-C(=NR 17 )R 15 、-C 0-8 Alkyl-C(O)NR 16 R 17 and -C 0-8 Alkyl-N(R 16 )-C(O)R 15 substituted by a substituent.

[0179] "Cycloalkoxy" or "cycloalkyloxy" refers to an -O-cycloalkyl group, wherein cycloalkyl is as defined above, for example, "C 3-12 "Cycloalkyloxy" refers to a cycloalkyloxy group containing 3 to 12 carbon atoms. 3-6 The term "cycloalkyloxy" refers to cycloalkyloxy groups containing 3 to 6 carbon atoms, including but not limited to cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, and the like.

[0180] "Cycloalkoxy" or "cycloalkyloxy" may be optionally substituted or unsubstituted. When substituted, the substituents are preferably one or more (preferably 1, 2, 3 or 4) of the following groups independently selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=NR 10 )R 11 、-C 0-8 Alkyl-N=S(O)R 11 R 12 、-C 0-8 Alkyl-N=SR 11 R 12 、-C 0-8 Alkyl-OS(O)2R 13 、-C 0-8 Alkyl-S(O) r R 13 、-C 0-8 Alkyl-OR 14 、-C 0-8 Alkyl-C(O)OR 14 、-C 0-8 Alkyl-C(O)SR 14 、-C 0-8 Alkyl-SC(O)R 15 、-C 0-8 Alkyl-C(O)R 15 、-C 0-8 Alkyl-OC(O)R 15 、-C 0-8 Alkyl-P(O)(R 15 )2. -C 0-8 Alkyl-NR 16 R 17 、-C 0-8 Alkyl-C(=NR 16 )R 15 、-C 0-8 Alkyl-N(R 16 )-C(=NR 17 )R 15 、-C 0-8 Alkyl-C(O)NR 16 R 17 and -C0-8 Alkyl-N(R 16 )-C(O)R 15 substituted by a substituent.

[0181] "Heterocyclyloxy" or "heterocyclyloxy" refers to an -O-heterocyclyl group wherein heterocyclyl is as defined above and includes, but is not limited to, azetidinyloxy, oxetanyloxy, azopentyloxy, nitrogen, oxhexyloxy, and the like.

[0182] "Heterocyclyloxy" or "heterocyclyloxy" may be optionally substituted or unsubstituted. When substituted, the substituents are preferably one or more (preferably 1, 2, 3 or 4) of the following groups independently selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=NR 10 )R 11 、-C 0-8 Alkyl-N=S(O)R 11 R 12 、-C 0-8 Alkyl-N=SR 11 R 12 、-C 0-8 Alkyl-OS(O)2R 13 、-C 0-8 Alkyl-S(O) r R 13 、-C 0-8 Alkyl-OR 14 、-C 0-8 Alkyl-C(O)OR 14 、-C 0-8 Alkyl-C(O)SR 14 、-C 0-8 Alkyl-SC(O)R 15 、-C 0-8 Alkyl-C(O)R 15 、-C 0-8 Alkyl-OC(O)R 15 、-C 0-8 Alkyl-P(O)(R 15 )2. -C 0-8 Alkyl-NR 16 R17 、-C 0-8 Alkyl-C(=NR 16 )R 15 、-C 0-8 Alkyl-N(R 16 )-C(=NR 17 )R 15 、-C 0-8 Alkyl-C(O)NR 16 R 17 and -C 0-8 Alkyl-N(R 16 )-C(O)R 15 substituted by a substituent.

[0183] “C 1-10 "Alkanoyl" refers to C 1-10 The monovalent atomic group remaining after removing the hydroxyl group from the alkyl acid is usually expressed as "C 0-9 "C1 alkyl-C(O)-" refers to acetyl; "C2 alkyl-C(O)-" refers to propionyl; "C3 alkyl-C(O)-" refers to butyryl or isobutyryl.

[0184] "-C 0-8 Alkyl-S(O)(=NR 10 )R 11 " refers to -S(O)(=NR 10 )R 11 The sulfur atom in the 0-8 On the alkyl group, where C 0-8 The alkyl group is as defined above.

[0185] "-C 0-8 Alkyl-N=S(O)R 11 R 12 " refers to -N=S(O)R 11 R 12 The nitrogen atom in the 0-8 On the alkyl group, where C 0-8 Alkyl is as defined above.

[0186] "-C 0-8 Alkyl-N=SR 11 R 12 " refers to -N = SR 11 R 12 The nitrogen atom in the 0-8 On the alkyl group, where C 0-8 The alkyl group is as defined above.

[0187] "-C 0-8 Alkyl-OS(O)2R 13 ” refers to -OS(O)2R13 The oxygen atom in the 0-8 On the alkyl group, where C 0-8 The alkyl group is as defined above.

[0188] "-C 0-8 Alkyl-S(O) r R 13 ” refers to -S(O) r R 13 The sulfur atom in the 0-8 On the alkyl group, where C 0-8 The alkyl group is as defined above.

[0189] "-C 0-8 Alkyl-P(O)(R 15 )2” refers to -P(O)(R 15 )2 in which the phosphorus atom is connected to the C 0-8 On the alkyl group, where C 0-8 The alkyl group is as defined above.

[0190] "-C 0-8 Alkyl-OR 14 " refers to -OR 14 The oxygen atom in the 0-8 On the alkyl group, where C 0-8 The alkyl group is as defined above.

[0191] "-C 0-8 Alkyl-C(O)OR 14 " refers to -C(O)OR 14 The carbonyl group is connected to C 0-8 On the alkyl group, where C 0-8 The alkyl group is as defined above.

[0192] "-C 0-8 Alkyl-C(O)SR 14 ” refers to -C(O)SR 14 The carbonyl group is connected to C 0-8 On the alkyl group, where C 0-8 The alkyl group is as defined above.

[0193] "-C 0-8 Alkyl-SC(O)R 15 ” refers to -SC(O)R 15 The sulfur atom in the 0-8 On the alkyl group, where C 0-8 The alkyl group is as defined above.

[0194] "-C 0-8 Alkyl-C(O)R 15 ” refers to -C(O)R 15The carbonyl group is connected to C 0-8 On the alkyl group, where C 0-8 The alkyl group is as defined above.

[0195] "-C 0-8 Alkyl-OC(O)R 15 ” refers to -OC(O)R 15 The oxygen atom in the 0-8 On the alkyl group, where C 0-8 The alkyl group is as defined above.

[0196] "-C 0-8 Alkyl-NR 16 R 17 ”-NR 16 R 17 The nitrogen atom in the 0-8 On the alkyl group, where C 0-8 The alkyl group is as defined above.

[0197] "-C 0-8 Alkyl-C(=NR 16 )R 15 " refers to -C(=NR 16 )R 15 The carbon atoms in the 0-8 On the alkyl group, where C 0-8 The alkyl group is as defined above.

[0198] "-C 0-8 Alkyl-N(R 16 )-C(=NR 17 )R 15 ” refers to -N(R 16 )-C(=NR 17 )R 15 The nitrogen atom in the 0-8 On the alkyl group, where C 0-8 The alkyl group is as defined above.

[0199] "-C 0-8 Alkyl-C(O)NR 16 R 17 ” refers to -C(O)NR 16 R 17 The carbonyl group is connected to C 0-8 On the alkyl group, where C 0-8 The alkyl group is as defined above.

[0200] "-C 0-8 Alkyl-N(R 16 )-C(O)R 15 ” refers to -N(R 16 )-C(O)R 15The nitrogen atom in the 0-8 On the alkyl group, where C 0-8 The alkyl group is as defined above.

[0201] "Halogen-substituted C 1-10 The term "alkyl" refers to an alkyl group of 1 to 10 carbon atoms in which the hydrogen atoms on the alkyl group are optionally replaced by fluorine, chlorine, bromine or iodine atoms, including but not limited to difluoromethyl, dichloromethyl, dibromomethyl, trifluoromethyl, trichloromethyl and tribromomethyl.

[0202] "Halogen-substituted C 1-10 "Alkoxy" refers to an alkoxy group of 1-10 carbon atoms in which the hydrogen atoms on the alkyl group are optionally replaced by fluorine, chlorine, bromine or iodine atoms. It includes but is not limited to difluoromethoxy, dichloromethoxy, dibromomethoxy, trifluoromethoxy, trichloromethoxy, tribromomethoxy and the like.

[0203] "Deuterium replaces C 1-10 "Alkyl" refers to an alkyl group of 1 to 10 carbon atoms in which the hydrogen atoms on the alkyl group are optionally replaced by deuterium atoms, including but not limited to monodeuteriomethyl, dideuteriomethyl, trideuteriomethyl, etc.

[0204] "Halogen" refers to fluorine, chlorine, bromine or iodine.

[0205] "Optional" or "optionally" means that the subsequently described event or circumstance may but need not occur, and the description includes instances where the event or circumstance occurs or does not occur, i.e., includes both substituted and unsubstituted instances. For example, "a heterocyclic group optionally substituted with an alkyl group" means that an alkyl group may but need not be present, and the description includes both instances where the heterocyclic group is substituted with an alkyl group and where the heterocyclic group is not substituted with an alkyl group.

[0206] "Substituted" means that one or more "hydrogen atoms" in a group are independently replaced by a corresponding number of substituents. It goes without saying that the substituents are only in their possible chemical positions, consistent with chemical valence theory, and those skilled in the art can determine (by experiment or theory) possible or impossible substitutions without undue effort. For example, amino or hydroxy groups with free hydrogens may be unstable when combined with carbon atoms with unsaturated bonds (such as olefins).

[0207] "Stereoisomers," whose English name is stereoisomer, refer to isomers resulting from the different spatial arrangements of atoms in a molecule. They can be divided into two types: cis-trans isomers and enantiomers, or into two major categories: enantiomers and diastereomers. Stereoisomers caused by rotation about single bonds are called conformational stereoisomers, sometimes also called rotamers. Stereoisomers caused by bond length, bond angle, the presence of double bonds or rings in the molecule are called configuration stereoisomers, which are further divided into two categories. Among them, isomers caused by the inability to rotate freely around double bonds or single bonds of ring carbon atoms are called geometric isomers, also called cis-trans isomers, and are divided into two configurations: Z and E. For example, cis-2-butene and trans-2-butene are a pair of geometric isomers. Stereoisomers with different optical rotation properties due to the lack of anti-axial symmetry in the molecule are called optical isomers and are divided into R and S configurations. In this invention, "stereoisomers," unless otherwise specified, are understood to include one or more of the aforementioned enantiomers, configurational isomers, and conformational isomers.

[0208] "Pharmaceutically acceptable salt" in the present invention refers to pharmaceutically acceptable acid addition salts, including inorganic acid salts and organic acid salts, which can be prepared by methods known in the art.

[0209] A "pharmaceutical composition" refers to a mixture containing one or more compounds described herein, or their physiologically / pharmaceutically acceptable salts or prodrugs, together with other chemical components, as well as other components such as physiologically / pharmaceutically acceptable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration to an organism, facilitating absorption of the active ingredient and thereby exerting its biological activity.

[0210] The present invention will be further described in detail and completely below with reference to the embodiments, but the present invention is by no means limited thereto, and the present invention is not limited to the contents of the embodiments.

[0211] The structures of the compounds of the present invention are determined by nuclear magnetic resonance (NMR) and / or liquid chromatography-mass spectrometry (LC-MS). NMR chemical shifts (δ) are given in parts per million (ppm). NMR measurements are performed using a Bruker AVANCE-400 / 500 NMR spectrometer, using deuterated dimethyl sulfoxide (DMSO-d6), deuterated methanol (CD3OD / MeOH-d4), and deuterated chloroform (CDCl3) as the solvents, with tetramethylsilane (TMS) as the internal standard.

[0212] Liquid chromatography-mass spectrometry (LC-MS) was performed using an Agilent 6120 mass spectrometer. HPLC was performed using an Agilent 1200DAD high-pressure liquid chromatograph (Sunfire C18 150×4.6 mm column) and a Waters 2695-2996 high-pressure liquid chromatograph (Gimini C18 150×4.6 mm column).

[0213] Thin layer chromatography silica gel plates use Yantai Huanghai HSGF254 or Qingdao GF254 silica gel plates. The specifications used for TLC are 0.15mm-0.20mm, and the specifications used for thin layer chromatography separation and purification products are 0.4mm-0.5mm. Column chromatography generally uses Yantai Huanghai silica gel 200-300 mesh silica gel as the carrier.

[0214] The starting materials in the examples of the present invention are known and can be purchased commercially, or can be synthesized using or according to methods known in the art.

[0215] Unless otherwise specified, all reactions of the present invention are carried out under continuous magnetic stirring in a dry nitrogen or argon atmosphere, with dry solvents and reaction temperatures expressed in degrees Celsius (°C).

[0216] Preparation of Examples

[0217] Example 1: Preparation of 1-(5-((5-chloro-2-(((3S,4R)-3-hydroxytetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)ethynyl)-1-isopropyl-1H-imidazol-2-yl)ethan-1-one

[0218] Step 1: Synthesis of 2,5-diiodo-1-isopropyl-1H-imidazole

[0219] Dissolve N,N,N,N-tetramethylethylenediamine (10 mL, 66 mmol) in n-pentane (28 mL). Under nitrogen, add n-butyllithium (26.400 mL, 2.5 M) in n-hexane with stirring at -78°C. Then, add 1-isopropylimidazole (3.0 mL, 26 mmol) dropwise. The solution is slowly returned to room temperature and stirred for 1 hour. After dilution with tetrahydrofuran (50 mL), the mixture is cooled to -78°C. Iodine (16.75 g, 66.00 mmol) is then dissolved in tetrahydrofuran (80 mL) and added dropwise to the reaction system at -78°C. Stirring is continued for 1.5 hours, then slowly returned to room temperature and stirred overnight. Ethyl acetate (10 mL) is added to quench the reaction. The reaction solution was concentrated and then separated using silica gel column chromatography [eluent: 0%-60% ethyl acetate dissolved in petroleum ether] to obtain 2,5-diiodo-1-isopropyl-1H-imidazole (5.21 g, yield: 55%). MS (ESI): m / z 362.8 [M+H] + .

[0220] Step 2: Synthesis of 1-(5-iodo-1-isopropyl-1H-imidazol-2-yl)ethan-1-one

[0221] 2,5-Diiodo-1-isopropyl-1H-imidazole (4.21 g, 11.631 mmol) was dissolved in tetrahydrofuran (40 mL) under nitrogen and cooled to -78°C. Then, n-butyllithium (5.1 mL, 2.5 M) in n-hexane was added and stirred at -78°C for 30 minutes. The mixture was then allowed to return to room temperature and stirred for another 30 minutes. N-Methoxy-N-methylacetamide (1.2 mL, 11.631 mmol) was dissolved in tetrahydrofuran (40 mL) and added dropwise to the reaction system at -78°C. The reaction system was then slowly allowed to return to room temperature and stirred overnight. Ethyl acetate (10 mL) was added to quench the mixture. The reaction solution was concentrated and separated by silica gel column chromatography (eluent: 0% to 4% ethyl acetate in petroleum ether) to afford 1-(5-iodo-1-isopropyl-1H-imidazol-2-yl)ethan-1-one (2.20 g, yield: 68%). MS (ESI): m / z 279.0 [M+H] + .

[0222] Step 3: Synthesis of 1-(1-isopropyl-5-((trimethylsilyl)ethynyl)-1H-imidazol-2-yl)ethan-1-one

[0223] A Schlenk tube was charged with 1-(5-iodo-1-isopropyl-1H-imidazol-2-yl)ethan-1-one (1.60 g, 5.74 mmol), ethynyltrimethylsilane (2.5 mL, 17 mmol), tetrakis(triphenylphosphine)palladium (331.8 mg, 0.287 mmol), cuprous iodide (237.4 mg, 0.57 mmol), triethylamine (10 mL), and tetrahydrofuran (10 mL). The nitrogen atmosphere was purged three times, and the reaction mixture was stirred at 70°C overnight. The mixture was diluted with ethyl acetate (20 mL), filtered through silica gel (10 g) on ​​a fritted funnel, and washed twice with ethyl acetate (10 mL). The filtrate was concentrated to afford crude 1-(1-isopropyl-5-((trimethylsilyl)ethynyl)-1H-imidazol-2-yl)ethan-1-one, which was used directly in the next reaction.

[0224] Step 4: Synthesis of 1-(5-ethynyl-1-isopropyl-1H-imidazol-2-yl)ethan-1-one

[0225] 1-(1-isopropyl-5-((trimethylsilyl)ethynyl)-1H-imidazol-2-yl)ethan-1-one obtained in the previous step was dissolved in methanol (10 mL) and potassium carbonate (100 mg) was added. The reaction solution was stirred at room temperature for 3 hours. The mixture was diluted with dichloromethane (20 mL) and filtered through celite using a fritted funnel. The mixture was washed with ethyl acetate (10 mL). The filtrates were combined, concentrated, and then purified by silica gel column chromatography (eluent: 0% to 4% ethyl acetate in petroleum ether) to afford 1-(5-ethynyl-1-isopropyl-1H-imidazol-2-yl)ethan-1-one (757.0 mg, yield over two steps: 68%). MS (ESI): m / z 177.0 [M+H] + .

[0226] Step 5: Synthesis of 1-(5-((2,5-dichloropyrimidin-4-yl)ethynyl)-1-isopropyl-1H-imidazol-2-yl)ethan-1-one

[0227] To a Schlenk tube was added 1-(5-ethynyl-1-isopropyl-1H-imidazol-2-yl)ethan-1-one (264.2 mg, 1.50 mmol), 2,4,5-trichloropyrimidine (250 mg, 1.363 mmol), tetrakis(triphenylphosphine)palladium (78.75 mg, 0.068 mmol), cuprous iodide (0.011 mL, 0.136 mmol) and triethylamine (10 mL). The nitrogen atmosphere was purged three times, and the reaction mixture was stirred at 100°C overnight. The mixture was diluted with ethyl acetate (20 mL), filtered through a sand-core funnel using silica gel (10 g), and washed twice with ethyl acetate (10 mL). The filtrate was concentrated and then purified by silica gel column chromatography (0% to 4% ethyl acetate in petroleum ether as eluent) to afford 1-(5-((2,5-dichloropyrimidin-4-yl)ethynyl)-1-isopropyl-1H-imidazol-2-yl)ethan-1-one (286 mg, yield: 58.43%). MS (ESI): m / z 323.0 [M+H] + .

[0228] Step 6: Synthesis of 1-(5-((5-chloro-2-(((3S,4R)-3-hydroxytetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)ethynyl)-1-isopropyl-1H-imidazol-2-yl)ethan-1-one

[0229] Under nitrogen, 1-(5-((2,5-dichloropyrimidin-4-yl)ethynyl)-1-isopropyl-1H-imidazol-2-yl)ethan-1-one (200 mg, 0.473 mmol), (3S,4R)-4-aminotetrahydropyran-3-ol hydrochloride (61.79 mg, 0.402 mmol), and diisopropylethylamine (0.2 mL) were dissolved in acetonitrile (2 mL), and the reaction solution was stirred at 110°C overnight. Preparative chromatography was then used to obtain 1-(5-((5-chloro-2-(((3S,4R)-3-hydroxytetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)ethynyl)-1-isopropyl-1H-imidazol-2-yl)ethan-1-one (30 mg, yield: 23%). MS (ESI): m / z 404.2 [M+H] + .

[0230] 1H NMR (400MHz, CD3OD) δ8.36 (s, 1H), 7.60 (s, 1H), 5.86 (p, J = 6.9Hz, 1H), 3.94 (ddd,J=18.5,10.6,4.5Hz,3H),3.59(td,J=9.4,4.8Hz,1H),3.49(td,J=11 .7,2.2Hz,1H),3.21(dd,J=11.2,9.7Hz,1H),2.66(d,J=1.0Hz,3H),2.10(d d,J=12.7,3.2Hz,1H),1.70(d,J=7.0Hz,6H),1.62(qd,J=11.7,4.6Hz,1H).

[0231] Example 2: Preparation of (3S,4R)-4-((5-chloro-4-((2-(2-hydroxypropane-2-yl)-1-isopropyl-1H-imidazol-5-yl)ethynyl)pyrimidin-2-yl)amino)tetrahydro-2H-pyran-3-ol

[0232] Step 1: Synthesis of 2-(5-((2,5-dichloropyrimidin-4-yl)ethynyl)-1-isopropyl-1H-imidazol-2-yl)propan-2-ol

[0233] 1-(5-((2,5-dichloropyrimidin-4-yl)ethynyl)-1-isopropyl-1H-imidazol-2-yl)ethan-1-one (100 mg, 0.309 mmol) was dissolved in tetrahydrofuran (10 mL). Methylmagnesium bromide (0.5 mL, 3 M) in methyltetrahydrofuran was added at 0°C under nitrogen. The reaction mixture was stirred at 0°C for 1 hour. The solution was then slowly returned to room temperature and stirred for 30 minutes. Methanol (10 mL) was added to quench the reaction. The reaction mixture was concentrated and separated by preparative chromatography to afford 2-(5-((2,5-dichloropyrimidin-4-yl)ethynyl)-1-isopropyl-1H-imidazol-2-yl)propan-2-ol (30.0 mg, yield: 28.6%). MS (ESI): m / z 339.0 [M+H] + .

[0234] 1 H NMR (400MHz, CD3OD) δ8.79(s,1H),7.53(s,1H),5.67(hept,J=6.9Hz,1H),1.74(d,J=6.9Hz,6H),1.66(s,6H).

[0235] Step 2: Synthesis of (3S,4R)-4-((5-chloro-4-((2-(2-hydroxypropan-2-yl)-1-isopropyl-1H-imidazol-5-yl)ethynyl)pyrimidin-2-yl)amino)tetrahydro-2H-pyran-3-ol

[0236] Under nitrogen, 2-(5-((2,5-dichloropyrimidin-4-yl)ethynyl)-1-isopropyl-1H-imidazol-2-yl)propan-2-ol (30 mg, 0.088 mmol), (3S,4R)-4-aminotetrahydropyran-3-ol hydrochloride (14.94 mg, 0.097 mmol), and diisopropylethylamine (0.055 mL) were dissolved in acetonitrile (1 mL). The reaction solution was stirred at 80°C for 48 hours. Preparative chromatography was then used to obtain (3S,4R)-4-((5-chloro-4-((2-(2-hydroxypropan-2-yl)-1-isopropyl-1H-imidazol-5-yl)ethynyl)pyrimidin-2-yl)amino)tetrahydro-2H-pyran-3-ol (12 mg, yield: 32%). MS (ESI): m / z 420.2 [M+H] + .

[0237] 1 H NMR (400MHz, CD3OD) δ8.31(s,1H),7.39(s,1H),5.63(hept,J=6.9Hz,1H),4.00-3.87(m,3H),3.59(td,J=9.5,4.8Hz,1H),3.49(td,J=11.7 ,2.3Hz,1H),3.21(dd,J=11.2,9.7Hz,1H),2.10(ddd,J=13.5,4.7,2.3Hz,1H),1.73(dd,J=7.0,1.7Hz,6H),1.68-1.54(m,1H),1.65(s,6H).

[0238] Example 57: Preparation of 5-chloro-4-((5-isopropyl-1-methyl-1H-pyrazol-4-yl)ethynyl)-N-(5-(1-methylpiperidin-4-yl)pyridin-2-yl)pyrimidin-2-amine

[0239] Step 1: Synthesis of 5-chloro-4-((5-isopropyl-1-methyl-1H-pyrazol-4-yl)ethynyl)-N-(5-(1-methylpiperidin-4-yl)pyridin-2-yl)pyrimidin-2-amine

[0240] 2,5-Dichloro-4-((5-isopropyl-1-methyl-1H-pyrazol-4-yl)ethynyl)pyrimidine (50 mg, 0.169 mmol) was dissolved in toluene (2 mL) and tert-butanol (0.5 mL). 5-(1-methylpiperidin-4-yl)pyridin-2-amine (21.23 mg, 0.138 mmol), cesium carbonate (110.38 mg, 0.339 mmol), Pd2(dba)3 (15.51 mg, 0.017 mmol), and 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl (8.08 mg, 0.017 mmol) were added. The reaction mixture was stirred at 100°C overnight under a nitrogen atmosphere. The reaction mixture was filtered, and the filtrate was concentrated and analyzed by preparative liquid chromatography to obtain the product 5-chloro-4-((5-isopropyl-1-methyl-1H-pyrazol-4-yl)ethynyl)-N-(5-(1-methylpiperidin-4-yl)pyridin-2-yl)pyrimidin-2-amine (4.5 mg, yield: 8.84%). MS (ESI): m / z 450.2 [M+H] + .

[0241] 1 H NMR (400MHz, DMSO-d6) δ10.10(s,1H),8.63(s,1H),8.18(s,1H),8.04(d,J=8.6Hz,1H),7.74(s,1H),7.66(dd,J=8.7,2.5Hz,1H),3.85(s ,3H),3.29-3.25(m,1H),2.89-2.83(m,2H),2.47-2.42(m,1H),2.19(s,3H),2.00-1.91(m,2H),1.76-1.63(m,4H),1.43(d,J=7.0Hz,6H).

[0242] Example 126: Preparation of 3-(5-((5-chloro-2-(((3S,4R)-3-hydroxytetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)ethynyl)-1-isopropyl-1H-imidazol-2-yl)oxazolidin-2-one

[0243] Step 1: Synthesis of 5-chloro-2-(methylthio)-4-((triisopropylsilyl)ethynyl)pyrimidine

[0244] 4,5-Dichloro-2-(methylthio)pyrimidine (3.5 g, 17.943 mmol) was dissolved in DMF (35 mL). Pd(PPh3)2Cl2 (1.26 g, 1.794 mmol), CuI (0.34 g, 1.794 mmol), and DIPEA (6.96 g, 53.830 mmol) were added sequentially. The mixture was sealed under nitrogen and heated to 80°C with stirring overnight. After the reaction, most of the acetonitrile was removed, saturated ammonium chloride was added, and the mixture was extracted three times with ethyl acetate. The combined organic phases were washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated. 5-Chloro-2-(methylthio)-4-((triisopropylsilyl)ethynyl)pyrimidine (5.4 g, yield: 88%) was isolated by silica gel column chromatography (100% ethyl acetate-petroleum ether). MS (ESI): m / z 341.2 [M+H] + .

[0245] Step 2: Synthesis of 5-chloro-2-(methylsulfinyl)-4-((triisopropylsilyl)ethynyl)pyrimidine

[0246] 5-Chloro-2-(methylthio)-4-((triisopropylsilyl)ethynyl)pyrimidine (5.4 g, 15.836 mmol) was dissolved in DCM (100 mL), and mCPBA (5.14 g, 25.338 mmol) was added and stirred overnight. After the reaction was completed, the mixture was cooled to zero degrees and quenched with saturated sodium bicarbonate aqueous solution. The mixture was extracted three times with dichloromethane. The combined organic phases were washed with saturated sodium bicarbonate aqueous solution and saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated, and separated by silica gel column chromatography (50% ethyl acetate-petroleum ether system) to give 5-chloro-2-(methylsulfinyl)-4-((triisopropylsilyl)ethynyl)pyrimidine (4.71 g, yield: 83%). MS (ESI): m / z 357.2 [M+H] + .

[0247] Step 3: Synthesis of (3S,4R)-4-((5-chloro-4-((triisopropylsilyl)ethynyl)pyrimidin-2-yl)amino)tetrahydro-2H-pyran-3-ol

[0248] 5-Chloro-2-(methylsulfinyl)-4-((triisopropylsilyl)ethynyl)pyrimidine (2.5 g, 7.003 mmol), (3S,4R)-4-aminotetrahydropyran-3-ol hydrochloride (1.61 g, 10.505 mmol), and DIPEA (3.62 g, 28.013 mmol) were dissolved in DMA (25 mL), heated to 90°C, and stirred overnight. After completion of the reaction, the mixture was cooled to room temperature, quenched with water, and extracted three times with ethyl acetate. The combined organic phases were washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated. (3S,4R)-4-((5-chloro-4-((triisopropylsilyl)ethynyl)pyrimidin-2-yl)amino)tetrahydro-2H-pyran-3-ol (2.08 g, yield: 72%) was isolated by silica gel column chromatography (40% ethyl acetate-petroleum ether). MS (ESI): m / z 410.2 [M+H] + .

[0249] Step 4: Synthesis of (3S,4R)-4-((5-chloro-4-ethynylpyrimidin-2-yl)amino)tetrahydro-2H-pyran-3-ol

[0250] (3S,4R)-4-((5-chloro-4-((triisopropylsilyl)ethynyl)pyrimidin-2-yl)amino)tetrahydro-2H-pyran-3-ol (2.08 g, 5.073 mmol) was dissolved in THF (10 mL). A solution of TBAF in THF (6.087 mL, 6.087 mmol, 1.0 mol / L) was added under ice-cooling. The mixture was stirred under ice-cooling for 1 hour. The reaction was quenched by addition of saturated ammonium chloride and extracted three times with ethyl acetate. The combined organic phases were washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated. (3S,4R)-4-((5-chloro-4-ethynylpyrimidin-2-yl)amino)tetrahydro-2H-pyran-3-ol (1.2 g, yield: 93%) was isolated by silica gel column chromatography (50% ethyl acetate-petroleum ether). MS (ESI): m / z 254.2 [M+H] + .

[0251] Step 5: Synthesis of 3-(5-iodo-1-isopropyl-1H-imidazol-2-yl)oxazolidin-2-one

[0252] Dissolve 2,5-diiodo-1-isopropyl-1H-imidazole (600 mg, 1.658 mmol) in dioxane (3 mL), and add oxazolidin-2-one (721.76 mg, 8.288 mmol), CuI (63.14 mg, 0.332 mmol), KCO (458.18 mg, 3.315 mmol), and trans-(1R,2R)-N,N'-dimethyl-1,2-cyclohexanediamine (0.106 mL, 0.663 mmol) in sequence. Seal the tube under nitrogen, heat to 100°C, and stir overnight. After the reaction is complete, the reaction mixture is filtered, concentrated, and separated by silica gel column chromatography (20% ethyl acetate-petroleum ether) to afford 3-(5-iodo-1-isopropyl-1H-imidazol-2-yl)oxazolidin-2-one (320 mg, 0.997 mmol, 60.11%). MS (ESI): m / z 322.1 [M+H] + .

[0253] Step 6: Synthesis of 3-(5-((5-chloro-2-(((3S,4R)-3-hydroxytetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)ethynyl)-1-isopropyl-1H-imidazol-2-yl)oxazolidin-2-one

[0254] 3-(5-iodo-1-isopropyl-1H-imidazol-2-yl)oxazolidin-2-one (132.91 mg, 0.414 mmol) was dissolved in tetrahydrofuran (2 mL), and (3S,4R)-4-((5-chloro-4-ethynylpyrimidin-2-yl)amino)tetrahydro-2H-pyran-3-ol (70 mg, 0.276 mmol), CuI (5.26 mg, 0.028 mmol), tetrakistriphenylphosphine palladium (17.99 mg, 0.016 mmol), and DIPEA (0.137 mL, 0.828 mmol) were added. The reaction mixture was stirred at 50°C overnight under a nitrogen atmosphere. After the reaction, the reaction solution was diluted with water and then extracted three times with ethyl acetate. The combined organic phases were dried over anhydrous sodium sulfate, filtered, concentrated, and separated by silica gel column chromatography (20% methanol-dichloromethane system) to obtain a crude product. The crude product was separated by preparative liquid chromatography to obtain 3-(5-((5-chloro-2-(((3S,4R)-3-hydroxytetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)ethynyl)-1-isopropyl-1H-imidazol-2-yl)oxazolidin-2-one (41.6 mg, yield 33.74%). MS (ESI): m / z 447.2 [M+H] + .

[0255] 1H NMR (400MHz, DMSO-d6) δ8.43(s,1H),7.59(s,2H),4.94(d,J=5.3Hz,1H),4.65-4.54(m,3H),4.08-4.00(m,2H),3.84-3.73(m,3 H),3.54-3.41(m,1H),3.32-3.28(m,1H),3.03(t,J=10.4Hz,1H),1.93-1.83(m,1H),1.60(d,J=6.8Hz,6H),1.50-1.40(m,1H).

[0256] Examples 3 to 138 can be prepared by selecting corresponding raw materials according to all or part of the synthesis methods of Examples 1, 2, 57 or 126:

[0257] The NMR data of the compound prepared in the above example are as follows:

[0258] Biological test evaluation

[0259] 1. In vitro biochemical kinase activity analysis of CDK2 / cyclin E1

[0260] The present invention uses HTRF (homogeneous time-resolved fluorescence) assay to determine the inhibitory properties of compounds on CDK2 / cyclin E1 kinase activity. The specific experimental process is as follows:

[0261] 1. The kinase reaction performed in the present invention was performed in a 384-well plate, using 15 nM CDK2 / cyclin E1 kinase (Carna), 1 μM ATP, and 1 μM biotin-labeled substrate protein ATF2-biotin (Cisbio) in a reaction system of 10 mM MgCl2, 1 mM MnCl2, 1 mM DTT, and basic kinase buffer (Cisbio) and incubating the reaction at room temperature for 90 minutes.

[0262] 2. Add detection solution (Cisbio, containing reagents that can specifically recognize phosphorylated ATF2 and ATF2-biotin protein, respectively), apply sealing film (protect from light and prevent evaporation) and incubate at 25°C for 60 minutes.

[0263] 3. Transfer the plate to Envision to read the data to measure the energy transfer (FRET) signal (read the emission light at 665nM and 615nM wavelengths respectively to calculate the 665 / 615 ratio).

[0264] 4. Use the 205 model in XLfit statistical software to analyze the inhibition rate at different compound concentrations to determine the IC 50 The enzymatic activities of the compounds in the specific examples are shown in Table 1.

[0265] II. In vitro biochemical kinase activity analysis of CDK4 / cyclin D3

[0266] The present invention uses an HTRF assay to determine the inhibitory properties of compounds on CDK4 / cyclin D3 activity. The specific experimental process is as follows:

[0267] 1. The kinase reaction performed in the present invention was performed in a 384-well plate, using 4.9 nM CDK4 / cyclin D3 (Carna), 1 mM (or 80 μM) ATP, and 0.3 μM biotin-labeled substrate protein Rb-biotin (Cisbio) in a reaction system of 50 mM MgCl2, 1 mM DTT, and basic kinase buffer (Cisbio) for incubation at 30°C for 90 minutes.

[0268] 2. Add detection solution (Cisbio, containing reagents that can specifically recognize phosphorylated Rb and Rb-biotin protein, respectively), apply sealing film (protect from light and prevent evaporation) and incubate at 25°C for 60 minutes.

[0269] 3. Transfer the plate to Envision to read the data to measure the FRET signal (read the emission light at 665nM and 615nM wavelengths respectively to calculate the 665 / 615 ratio).

[0270] 4. Use the 205 model in XLfit statistical software to analyze the inhibition rate at different compound concentrations to determine the IC 50 The enzymatic activities of the compounds in the specific examples are shown in Table 1.

[0271] III. In vitro biochemical kinase activity analysis of CDK6 / cyclin D3

[0272] The present invention uses an HTRF assay to determine the inhibitory properties of compounds on CDK6 / cyclin D3 activity. The specific experimental process is as follows:

[0273] 1. The kinase reaction performed in the present invention was performed in a 384-well plate, using 0.02 nM CDK6 / cyclin D3 (Carna), 1 mM (or 100 μM) ATP, and 0.3 μM biotin-labeled substrate protein Rb-biotin (Cisbio) in a reaction system of 5 mM MgCl2, 1 mM DTT, and basic kinase buffer (Cisbio) for incubation at 30°C for 60 minutes.

[0274] 2. Add detection solution (Cisbio, containing reagents that can specifically recognize phosphorylated Rb and Rb-biotin protein, respectively), apply sealing film (protect from light and prevent evaporation) and incubate at 25°C for 60 minutes.

[0275] 3. Transfer the plate to Envision to read the data to measure the FRET signal (read the emission light at 665nM and 615nM wavelengths respectively to calculate the 665 / 615 ratio).

[0276] 4. Use the 205 model in XLfit statistical software to analyze the inhibition rate at different compound concentrations to determine the IC 50 The enzymatic activities of the compounds of the specific examples are shown in the table below.

[0277] Table 1 Activity test results of compounds (Km ATP)

[0278] From the biological activity data of the compounds in the above specific examples, it can be seen that the series of compounds of the present invention have a strong inhibitory effect on CDK4 kinase, and some compounds have a high selectivity for CDK2 kinase and / or CDK6 kinase.

[0279] All documents mentioned in this application are incorporated herein by reference, just as if each document were incorporated herein by reference individually. It should also be understood that after reading the above disclosure, those skilled in the art may make various changes or modifications to the present invention, and that such equivalents also fall within the scope of the claims appended hereto.

Claims

1. A compound of formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof: in, Indicates a double bond or a single bond; X1 is CR4 or N; X2 is selected from CR5 or N; Y is N, CR 6a , NR 6b , CR 6c R 6d , O or S; Z is N, CR 7a NR 7b , CR 7c R 7d , O or S; W is N, CR 8a , NR 8b , CR 8c R 8d , O or S; Q is N, CR 9a , NR 9b , CR 9c R 9d , O or S; Ring A is C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl; Each R1 is independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, C 3-10 Cycloalkyl substituted C 1-4 Alkyl, 3-10 membered heterocyclic substituted C 1-4 Alkyl, C 6-10 Aryl substituted C 1-4 Alkyl, 5-10 membered heteroaryl substituted C 1-4 Alkyl, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=NR 10 )R 11 , -C 0-8 Alkyl-N=S(O)R 11 R 12 , -C 0-8 Alkyl-N=SR 11 R 12 , -C 0-8 Alkyl-OS(O)2R 13 , -C 0-8 Alkyl-S(O) r R 13 , -C 0-8 Alkyl-OR 14 , -C 0-8 Alkyl-C(O)OR 14 , -C 0-8 Alkyl-C(O)SR 14 , -C 0-8 Alkyl-SC(O)R 15 , -C 0-8 Alkyl-C(O)R 15 , -C 0-8 Alkyl-OC(O)R 15 , -C 0-8 Alkyl-P(O)(R 15 2. -C 0-8 Alkyl-NR 16 R 17 , -C 0-8 Alkyl-C(=NR 16 )R 15 , -C 0-8 Alkyl-N(R 16 )-C(=NR 17 )R 15 , -C 0-8 Alkyl-C(O)NR 16 R 17 and -C 0-8 Alkyl-N(R 16 )-C(O)R 15 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=NR 10 )R 11 , -C 0-8 Alkyl-N=S(O)R 11 R 12 , -C 0-8 Alkyl-N=SR 11 R 12 , -C 0-8 Alkyl-OS(O)2R 13 , -C 0-8 Alkyl-S(O) r R 13 , -C 0-8 Alkyl-OR 14 , -C 0-8 Alkyl-C(O)OR 14 , -C 0-8 Alkyl-C(O)SR 14 , -C 0-8 Alkyl-SC(O)R 15 , -C 0-8 Alkyl-C(O)R 15 , -C 0-8 Alkyl-OC(O)R 15 , -C 0-8 Alkyl-P(O)(R 15 2. -C 0-8 Alkyl-NR 16 R 17 , -C 0-8 Alkyl-C(=NR 16 )R 15 , -C 0-8 Alkyl-N(R 16 )-C(=NR 17 )R 15 , -C 0-8 Alkyl-C(O)NR 16 R 17 and -C 0-8 Alkyl-N(R 16 )-C(O)R 15 The above groups are independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=NR 10 )R 11 , -C 0-8 Alkyl-N=S(O)R 11 R 12 , -C 0-8 Alkyl-N=SR 11 R 12 , -C 0-8 Alkyl-OS(O)2R 13 , -C 0-8 Alkyl-S(O) r R 13 , -C 0-8 Alkyl-OR 14 , -C 0-8 Alkyl-C(O)OR 14 , -C 0-8 Alkyl-C(O)SR 14 , -C 0-8 Alkyl-SC(O)R 15 , -C 0-8 alkyl -C(O)R 15 , -C 0-8 Alkyl-OC(O)R 15 , -C 0-8 Alkyl-P(O)(R 15 2. -C 0-8 Alkyl-NR 16 R 17 , -C 0-8 Alkyl-C(=NR 16 )R 15 , -C 0-8 Alkyl-N(R 16 )-C(=NR 17 )R 15 , -C 0-8 Alkyl-C(O)NR 16 R 17 and -C 0-8 Alkyl-N(R 16 )-C(O)R 15 substituted by a substituent; R2 is selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=NR 10 )R 11 , -C 0-4 Alkyl-N=S(O)R 11 R 12 , -C 0-4 Alkyl-N=SR 11 R 12 , -C 0-4 Alkyl-OS(O)2R 13 , -C 0-4 Alkyl-S(O) r R 13 , -C 0-4 Alkyl-OR 14 , -C 0-4 Alkyl-C(O)OR 14 , -C 0-4 Alkyl-C(O)SR 14 , -C 0-4 Alkyl-SC(O)R 15 , -C 0-4 Alkyl-C(O)R 15 , -C 0-4 Alkyl-OC(O)R 15 , -C 0-4 Alkyl-P(O)(R 15 2. -C 0-4 Alkyl-NR 16 R 17 , -C 0-4 Alkyl-C(=NR 16 )R 15 , -C 0-4 Alkyl-N(R 16 )-C(=NR 17 )R 15 , -C 0-4 Alkyl-C(O)NR 16 R 17 and -C 0-4 Alkyl-N(R 16 )-C(O)R 15 , provided that when ring A is C 3-6 When it is a cycloalkyl group or a 3-6 membered heterocyclic group, R2 is not hydrogen; R3 is selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=NR 10 )R 11 , -C 0-8 Alkyl-N=S(O)R 11 R 12 , -C 0-8 Alkyl-N=SR 11 R 12 , -C 0-8 Alkyl-OS(O)2R 13 , -C 0-8 Alkyl-S(O) r R 13 , -C 0-8 Alkyl-OR 14 , -C 0-8 Alkyl-C(O)OR 14 , -C 0-8 Alkyl-C(O)SR 14 , -C 0-8 Alkyl-SC(O)R 15 , -C 0-8 Alkyl-C(O)R 15 , -C 0-8 Alkyl-OC(O)R 15 , -C 0-8 Alkyl-P(O)(R 15 2. -C 0-8 Alkyl-NR 16 R 17 , -C 0-8 Alkyl-C(=NR 16 )R 15 , -C 0-8 Alkyl-N(R 16 )-C(=NR 17 )R 15 , -C 0-8 Alkyl-C(O)NR 16 R 17 and -C 0-8 Alkyl-N(R 16 )-C(O)R 15 ; R4 is selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=NR 10 )R 11 , -C 0-8 Alkyl-N=S(O)R 11 R 12 , -C 0-8 Alkyl-N=SR 11 R 12 , -C 0-8 Alkyl-OS(O)2R 13 , -C 0-8 Alkyl-S(O) r R 13 , -C 0-8 Alkyl-OR 14 , -C 0-8 Alkyl-C(O)OR 14 , -C 0-8 Alkyl-C(O)SR 14 , -C 0-8 Alkyl-SC(O)R 15 , -C 0-8 Alkyl-C(O)R 15 , -C 0-8 Alkyl-OC(O)R 15 , -C 0-8 Alkyl-P(O)(R 15 2. -C 0-8 Alkyl-NR 16 R 17 , -C 0-8 Alkyl-C(=NR 16 )R 15 , -C 0-8 Alkyl-N(R 16 )-C(=NR 17 )R 15 , -C 0-8 Alkyl-C(O)NR 16 R 17 and -C 0-8 Alkyl-N(R 16 )-C(O)R 15 ; R5 is selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=NR 10 )R 11 , -C 0-8 Alkyl-N=S(O)R 11 R 12 , -C 0-8 Alkyl-N=SR 11 R 12 , -C 0-8 Alkyl-OS(O)2R 13 , -C 0-8 Alkyl-S(O) r R 13 , -C 0-8 Alkyl-OR 14 , -C 0-8 Alkyl-C(O)OR 14 , -C 0-8 Alkyl-C(O)SR 14 , -C 0-8 Alkyl-SC(O)R 15 , -C 0-8 Alkyl-C(O)R 15 , -C 0-8 Alkyl-OC(O)R 15 , -C 0-8 Alkyl-P(O)(R 15 2. -C 0-8 Alkyl-NR 16 R 17 , -C 0-8 Alkyl-C(=NR 16 )R 15 , -C 0-8 Alkyl-N(R 16 )-C(=NR 17 )R 15 , -C 0-8 Alkyl-C(O)NR 16 R 17 and -C 0-8 Alkyl-N(R 16 )-C(O)R 15 ; R 6a , R 7a , R 8a and R 9a are each independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=NR 10 )R 11 , -C 0-8 Alkyl-N=S(O)R 11 R 12 , -C 0-8 Alkyl-N=SR 11 R 12 , -C 0-8 Alkyl-OS(O)2R 13 , -C 0-8 Alkyl-S(O) r R 13 , -C 0-8 Alkyl-OR 14 , -C 0-8 Alkyl-C(O)OR 14 , -C 0-8 alkyl -C(O)SR 14 , -C 0-8 Alkyl-SC(O)R 15 , -C 0-8 Alkyl-C(O)R 15 , -C 0-8 Alkyl-OC(O)R 15 , -C 0-8 Alkyl-P(O)(R 15 2. -C 0-8 Alkyl-NR 16 R 17 , -C 0-8 Alkyl-C(=NR 16 )R 15 , -C 0-8 Alkyl-N(R 16 )-C(=NR 17 )R 15 , -C 0-8 Alkyl-C(O)NR 16 R 17 and -C 0-8 Alkyl-N(R 16 )-C(O)R 15 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=NR 10 )R 11 , -C 0-8 Alkyl-N=S(O)R 11 R 12 , -C 0-8 Alkyl-N=SR 11 R 12 , -C 0-8 Alkyl-OS(O)2R 13 , -C 0-8 Alkyl-S(O) r R 13 , -C 0-8 Alkyl-OR 14 , -C 0-8 Alkyl-C(O)OR 14 , -C 0-8 Alkyl-C(O)SR 14 , -C 0-8 Alkyl-SC(O)R 15 , -C 0-8 Alkyl-C(O)R 15 , -C 0-8 Alkyl-OC(O)R 15 , -C 0-8 Alkyl-P(O)(R 15 2. -C 0-8 Alkyl-NR 16 R 17 , -C 0-8 Alkyl-C(=NR 16 )R 15 , -C 0-8 Alkyl-N(R 16 )-C(=NR 17 )R 15 , -C 0-8 Alkyl-C(O)NR 16 R 17 and -C 0-8 Alkyl-N(R 16 )-C(O)R 15 The above groups are independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=NR 10 )R 11 , -C 0-8 Alkyl-N=S(O)R 11 R 12 , -C 0-8 Alkyl-N=SR 11 R 12 , -C 0-8 Alkyl-OS(O)2R 13 , -C 0-8 Alkyl-S(O) r R 13 , -C 0-8 Alkyl-OR 14 , -C 0-8 Alkyl-C(O)OR 14 , -C 0-8 Alkyl-C(O)SR 14 , -C 0-8 Alkyl-SC(O)R 15 , -C 0-8 Alkyl-C(O)R 15 , -C 0-8 Alkyl-OC(O)R 15 , -C 0-8 Alkyl-P(O)(R 15 2. -C 0-8 Alkyl-NR 16 R 17 , -C 0-8 Alkyl-C(=NR 16 )R 15 , -C 0-8 Alkyl-N(R 16 )-C(=NR 17 )R 15 , -C 0-8 Alkyl-C(O)NR 16 R 17 and -C 0-8 Alkyl-N(R 16 )-C(O)R 15 substituted by a substituent; R 6b , R 7b , R 8b and R 9b Selected from hydrogen, deuterium, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-S(O)(=NR 10 )R 11 , -C 0-8 Alkyl-S(O) r R 13 , -C 0-8 Alkyl-C(O)OR 14 , -C 0-8 Alkyl-C(O)SR 14 , -C 0-8 Alkyl-C(O)R 15 , -C 0-8 Alkyl-P(O)(R 15 2. -C 0-8 Alkyl-C(=NR 16 )R 15 and -C 0-8 Alkyl-C(O)NR 16 R 17 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=NR 10 )R 11 , -C 0-8 Alkyl-N=S(O)R 11 R 12 , -C 0-8 Alkyl-N=SR 11 R 12 , -C 0-8 Alkyl-OS(O)2R 13 , -C 0-8 Alkyl-S(O) r R 13 , -C 0-8 Alkyl-OR 14 , -C 0-8 Alkyl-C(O)OR 14 , -C 0-8 Alkyl-C(O)SR 14 , -C 0-8 Alkyl-SC(O)R 15 , -C 0-8 Alkyl-C(O)R 15 , -C 0-8 Alkyl-OC(O)R 15 , -C 0-8 Alkyl-P(O)(R 15 2. -C 0-8 Alkyl-NR 16 R 17 , -C 0-8 Alkyl-C(=NR 16 )R 15 , -C 0-8 Alkyl-N(R 16 )-C(=NR 17 )R 15 , -C 0-8 Alkyl-C(O)NR 16 R 17 and -C 0-8 Alkyl-N(R 16 )-C(O)R 15 substituted by a substituent; Or, R 6b and R 7a Together with the part directly connected thereto, it forms a 3-10 membered heterocyclic group or a 5-10 membered heteroaryl group, wherein the above 3-10 membered heterocyclic group or the 5-10 membered heteroaryl group are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=NR 10 )R 11 , -C 0-8 Alkyl-N=S(O)R 11 R 12 , -C 0-8 Alkyl-N=SR 11 R 12 , -C 0-8 Alkyl-OS(O)2R 13 , -C 0-8 Alkyl-S(O) r R 13 , -C 0-8 Alkyl-OR 14 , -C 0-8 Alkyl-C(O)OR 14 , -C 0-8 Alkyl-C(O)SR 14 , -C 0-8 Alkyl-SC(O)R 15 , -C 0-8 Alkyl-C(O)R 15 , -C 0-8 Alkyl-OC(O)R 15 , -C 0-8 Alkyl-P(O)(R 15 2. -C 0-8 Alkyl-NR 16 R 17 , -C 0-8 Alkyl-C(=NR 16 )R 15 , -C 0-8 Alkyl-N(R 16 )-C(=NR 17 )R 15 , -C 0-8 alkyl -C(O)NR 16 R 17 and -C 0-8 Alkyl-N(R 16 )-C(O)R 15 substituted by a substituent; Or, R 6a and R 7b Together with the part directly connected thereto, it forms a 3-10 membered heterocyclic group or a 5-10 membered heteroaryl group, wherein the above 3-10 membered heterocyclic group or the 5-10 membered heteroaryl group are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=NR 10 )R 11 , -C 0-8 Alkyl-N=S(O)R 11 R 12 , -C 0-8 Alkyl-N=SR 11 R 12 , -C 0-8 Alkyl-OS(O)2R 13 , -C 0-8 Alkyl-S(O) r R 13 , -C 0-8 Alkyl-OR 14 , -C 0-8 Alkyl-C(O)OR 14 , -C 0-8 Alkyl-C(O)SR 14 , -C 0-8 Alkyl-SC(O)R 15 , -C 0-8 Alkyl-C(O)R 15 , -C 0-8 Alkyl-OC(O)R 15 , -C 0-8 Alkyl-P(O)(R 15 2. -C 0-8 Alkyl-NR 16 R 17 , -C 0-8 Alkyl-C(=NR 16 )R 15 , -C 0-8 Alkyl-N(R 16 )-C(=NR 17 )R 15 , -C 0-8 Alkyl-C(O)NR 16 R 17 and -C 0-8 Alkyl-N(R 16 )-C(O)R 15 substituted by a substituent; R 6c , R 6d , R 7c , R 7d , R 8c , R 8d , R 9c and R 9d are each independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=NR 10 )R 11 , -C 0-8 Alkyl-N=S(O)R 11 R 12 , -C 0-8 Alkyl-N=SR 11 R 12 , -C 0-8 Alkyl-OS(O)2R 13 , -C 0-8 Alkyl-S(O) r R 13 , -C 0-8 Alkyl-OR 14 , -C 0-8 Alkyl-C(O)OR 14 , -C 0-8 Alkyl-C(O)SR 14 , -C 0-8 Alkyl-SC(O)R 15 , -C 0-8 Alkyl-C(O)R 15 , -C 0-8 Alkyl-OC(O)R 15 , -C 0-8 Alkyl-P(O)(R 15 2. -C 0-8 Alkyl-NR 16 R 17 , -C 0-8 Alkyl-C(=NR 16 )R 15 , -C 0-8 Alkyl-N(R 16 )-C(=NR 17 )R 15 , -C 0-8 Alkyl-C(O)NR 16 R 17 and -C 0-8 Alkyl-N(R 16 )-C(O)R 15 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-S(O)(=NR 10 )R 11 , -C 0-8 Alkyl-N=S(O)R 11 R 12 , -C 0-8 Alkyl-N=SR 11 R 12 , -C 0-8 Alkyl-OS(O)2R 13 , -C 0-8 Alkyl-S(O) r R 13 , -C 0-8 Alkyl-OR 14 , -C 0-8 Alkyl-C(O)OR 14 , -C 0-8 Alkyl-C(O)SR 14 , -C 0-8 Alkyl-SC(O)R 15 , -C 0-8 Alkyl-C(O)R 15 , -C 0-8 Alkyl-OC(O)R 15 , -C 0-8 Alkyl-P(O)(R 15 2. -C 0-8 Alkyl-NR 16 R 17 , -C 0-8 Alkyl-C(=NR 16 )R 15 , -C 0-8 Alkyl-N(R 16 )-C(=NR 17 )R 15 , -C 0-8 Alkyl-C(O)NR 16 R 17 and -C 0-8 Alkyl-N(R 16 )-C(O)R 15 substituted by a substituent; Each R 10 are each independently selected from hydrogen, deuterium, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-S(O) r R 13 , -C 0-8 Alkyl-C(O)OR 14 , -C 0-8 Alkyl-C(O)R 15 and -C 0-8 Alkyl-C(O)NR 16 R 17 The above groups are optionally further substituted with one or more selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-S(O) r R 13 , -C 0-8 Alkyl-OR 14 , -C 0-8 Alkyl-C(O)OR 14 , -C 0-8 Alkyl-C(O)R 15 , -C 0-8 Alkyl-OC(O)R 15 , -C 0-8 Alkyl-NR 16 R 17 , -C 0-8 Alkyl-C(=NR 16 )R 15 , -C 0-8 Alkyl-N(R 16 )-C(=NR 17 )R 15 , -C 0-8 Alkyl-C(O)NR 16 R 17 and -C 0-8 Alkyl-N(R 16 )-C(O)R 15 substituted by a substituent; Each R 11 and each R 12 are each independently selected from hydrogen, deuterium, hydroxyl, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 aryl and 5-10 membered heteroaryl, or, R 11 and R 12 Together with the sulfur atom directly connected thereto, it forms a 3-10 membered heterocyclic group, wherein the above group is optionally further substituted with one or more selected from deuterium, halogen cyano, nitro, azido, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-S(O) r R 13 , -C 0-8 Alkyl-OR 14 , -C 0-8 Alkyl-C(O)OR 14 , -C 0-8 Alkyl-C(O)R 15 , -C 0-8 Alkyl-OC(O)R 15 , -C 0-8 Alkyl-NR 16 R 17 , -C 0-8 Alkyl-C(=NR 16 )R 15 , -C 0-8 Alkyl-N(R 16 )-C(=NR 17 )R 15 , -C 0-8 Alkyl-C(O)NR 16 R 17 and -C 0-8 Alkyl-N(R 16 )-C(O)R 15 substituted by a substituent; Each R 13 are independently selected from hydrogen, deuterium, hydroxyl, C 1-10 Alkyl, C 2-10 Alkenyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl and -NR 16 R 17 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, hydroxyl, =O, C 1-10 Alkyl, C 1-10 Alkoxy, C 3-12 Cycloalkyl, C 3-12 Cycloalkoxy, 3-12 membered heterocyclic group, 3-12 membered heterocyclic group, C 6-10 Aryl, C 6-10 aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy and -NR 16 R 17 substituted by a substituent; Each R 14 independently selected from hydrogen, deuterium, C 1-10 Alkyl, C 2-10 Alkenyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, cyano, C 1-10 Alkyl, C 1-10 Alkoxy, C 3-12 Cycloalkyl, C 3-12 Cycloalkoxy, 3-12 membered heterocyclic group, 3-12 membered heterocyclic group, C 6-10 Aryl, C 6-10 aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy and -NR 16 R 17 substituted by a substituent; Each R 15 are independently selected from hydrogen, deuterium, hydroxyl, C 1-10 Alkyl, C 1-10 Alkoxy, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, C 3-12 Cycloalkoxy, 3-12 membered heterocyclic group, 3-12 membered heterocyclic group, C 6-10 Aryl, C 6-10 aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy and -NR 16 R 17 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, cyano, C 1-10 Alkyl, C 1-10 Alkoxy, C 3-12 Cycloalkyl, C 3-12 Cycloalkoxy, 3-12 membered heterocyclic group, 3-12 membered heterocyclic group, C 6-10 Aryl, C 6-10 aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy and -NR 16 R 17 substituted by a substituent; Each R 16 and R 17 are each independently selected from hydrogen, deuterium, hydroxyl, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, sulfinyl, sulfonyl, methylsulfonyl, isopropylsulfonyl, cyclopropylsulfonyl, p-toluenesulfonyl, aminosulfonyl, dimethylaminosulfonyl and C 1-10 Alkanoyl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 1-10 Alkoxy, C 3-12 Cycloalkyl, C 3-12 Cycloalkoxy, 3-12 membered heterocyclic group, 3-12 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy, amino, mono-C 1-10 Alkylamino, di-C 1-10 Alkylamino and C 1-10 substituted with an alkanoyl substituent; Or, R 16 and R 17 The nitrogen atom directly connected thereto forms a 4-10 membered heterocyclic group or a 5-10 membered heteroaryl group, wherein the 4-10 membered heterocyclic group or the 5-10 membered heteroaryl group is optionally further substituted by one or more selected from deuterium, halogen, hydroxyl, =O, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 1-10 Alkoxy, C 3-12 Cycloalkyl, C 3-12 Cycloalkoxy, 3-12 membered heterocyclic group, 3-12 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy, amino, mono-C 1-10 Alkylamino, di-C 1-10 Alkylamino and C 1-10 substituted with an alkanoyl substituent; m is 0, 1, 2 or 3; and, Each r is independently 0, 1 or 2.

2. The compound of formula (I) according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: Each R1 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, C 3-6 Cycloalkyl substituted C 1-4 Alkyl, 3-6 membered heterocyclic substituted C 1-4 Alkyl, C 6-8 Aryl substituted C 1-4 Alkyl, 5-8 membered heteroaryl substituted C 1-4 Alkyl, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=NR 10 )R 11 , -C 0-4 Alkyl-N=S(O)R 11 R 12 , -C 0-4 Alkyl-N=SR 11 R 12 , -C 0-4 Alkyl-OS(O)2R 13 , -C 0-4 Alkyl-S(O) r R 13 , -C 0-4 Alkyl-OR 14 , -C 0-4 Alkyl-C(O)OR 14 , -C 0-4 Alkyl-C(O)SR 14 , -C 0-4 Alkyl-SC(O)R 15 , -C 0-4 Alkyl-C(O)R 15 , -C 0-4 Alkyl-OC(O)R 15 , -C 0-4 Alkyl-P(O)(R 15 2. -C 0-4 Alkyl-NR 16 R 17 , -C 0-4 Alkyl-C(=NR 16 )R 15 , -C 0-4 Alkyl-N(R 16 )-C(=NR 17 )R 15 , -C 0-4 Alkyl-C(O)NR 16 R 17 and -C 0-4 Alkyl-N(R 16 )-C(O)R 15 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=NR 10 )R 11 , -C 0-4 Alkyl-N=S(O)R 11 R 12 , -C 0-4 Alkyl-N=SR 11 R 12 , -C 0-4 Alkyl-OS(O)2R 13 , -C 0-4 Alkyl-S(O) r R 13 , -C 0-4 Alkyl-OR 14 , -C 0-4 Alkyl-C(O)OR 14 , -C 0-4 Alkyl-C(O)SR 14 , -C 0-4 Alkyl-SC(O)R 15 , -C 0-4 Alkyl-C(O)R 15 , -C 0-4 Alkyl-OC(O)R 15 , -C 0-4 Alkyl-P(O)(R 15 2. -C 0-4 Alkyl-NR 16 R 17 , -C 0-4 Alkyl-C(=NR 16 )R 15 , -C 0-4 Alkyl-N(R 16 )-C(=NR 17 )R 15 , -C 0-4 Alkyl-C(O)NR 16 R 17 and -C 0-4 Alkyl-N(R 16 )-C(O)R 15 The above groups are independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=NR 10 )R 11 , -C 0-4 Alkyl-N=S(O)R 11 R 12 , -C 0-4 Alkyl-N=SR 11 R 12 , -C 0-4 Alkyl-OS(O)2R 13 , -C 0-4 Alkyl-S(O) r R 13 , -C 0-4 Alkyl-OR 14 , -C 0-4 Alkyl-C(O)OR 14 , -C 0-4 Alkyl-C(O)SR 14 , -C 0-4 Alkyl-SC(O)R 15 , -C 0-4 Alkyl-C(O)R 15 , -C 0-4 Alkyl-OC(O)R 15 , -C 0-4 Alkyl-P(O)(R 15 2. -C 0-4 Alkyl-NR 16 R 17 , -C 0-4 Alkyl-C(=NR 16 )R 15 , -C 0-4 Alkyl-N(R 16 )-C(=NR 17 )R 15 , -C 0-4 Alkyl-C(O)NR 16 R 17 and -C 0-4 Alkyl-N(R 16 )-C(O)R 15 substituted by a substituent; R2 is selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -SF5, -S(O)(=NR 10 )R 11 、-N=S(O)R 11 R 12 、-N=SR 11 R 12 、-OS(O)2R 13 、-S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)SR 14 、-SC(O)R 15 、-C(O)R 15 、-OC(O)R 15 、-P(O)(R 15 )2.-NR 16 R 17 、-C(=NR 16 )R 15 、-N(R 16 )-C(=NR 17 )R 15 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 , provided that when ring A is C 3-6 When it is a cycloalkyl group or a 3-6 membered heterocyclic group, R2 is not hydrogen; R3 is selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=NR 10 )R 11 , -C 0-4 Alkyl-N=S(O)R 11 R 12 , -C 0-4 Alkyl-N=SR 11 R 12 , -C 0-4 Alkyl-OS(O)2R 13 , -C 0-4 Alkyl-S(O) r R 13 , -C 0-4 Alkyl-OR 14 , -C 0-4 Alkyl-C(O)OR 14 , -C 0-4 Alkyl-C(O)SR 14 , -C 0-4 Alkyl-SC(O)R 15 , -C 0-4 Alkyl-C(O)R 15 , -C 0-4 Alkyl-OC(O)R 15 , -C 0-4 Alkyl-P(O)(R 15 2. -C 0-4 Alkyl-NR 16 R 17 , -C 0-4 Alkyl-C(=NR 16 )R 15 , -C 0-4 Alkyl-N(R 16 )-C(=NR 17 )R 15 , -C 0-4 Alkyl-C(O)NR 16 R 17 and -C 0-4 Alkyl-N(R 16 )-C(O)R 15 ; R4 is selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=NR 10 )R 11 , -C 0-4 Alkyl-N=S(O)R 11 R 12 , -C 0-4 Alkyl-N=SR 11 R 12 , -C 0-4 Alkyl-OS(O)2R 13 , -C 0-4 Alkyl-S(O) r R 13 , -C 0-4 Alkyl-OR 14 , -C 0-4 Alkyl-C(O)OR 14 , -C 0-4 Alkyl-C(O)SR 14 , -C 0-4 Alkyl-SC(O)R 15 , -C 0-4 Alkyl-C(O)R 15 , -C 0-4 Alkyl-OC(O)R 15 , -C 0-4 Alkyl-P(O)(R 15 2. -C 0-4 Alkyl-NR 16 R 17 , -C 0-4 Alkyl-C(=NR 16 )R 15 , -C 0-4 Alkyl-N(R 16 )-C(=NR 17 )R 15 , -C 0-4 Alkyl-C(O)NR 16 R 17 and -C 0-4 Alkyl-N(R 16 )-C(O)R 15 ; R5 is selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=NR 10 )R 11 , -C 0-4 Alkyl-N=S(O)R 11 R 12 , -C 0-4 Alkyl-N=SR 11 R 12 , -C 0-4 Alkyl-OS(O)2R 13 , -C 0-4 Alkyl-S(O) r R 13 , -C 0-4 Alkyl-OR 14 , -C 0-4 Alkyl-C(O)OR 14 , -C 0-4 Alkyl-C(O)SR 14 , -C 0-4 Alkyl-SC(O)R 15 , -C 0-4 Alkyl-C(O)R 15 , -C 0-4 Alkyl-OC(O)R 15 , -C 0-4 Alkyl-P(O)(R 15 2. -C 0-4 Alkyl-NR 16 R 17 , -C 0-4 Alkyl-C(=NR 16 )R 15 , -C 0-4 Alkyl-N(R 16 )-C(=NR 17 )R 15 , -C 0-4 Alkyl-C(O)NR 16 R 17 and -C 0-4 Alkyl-N(R 16 )-C(O)R 15 ; R 6a , R 7a , R 8a and R 9a are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=NR 10 )R 11 , -C 0-4 Alkyl-N=S(O)R 11 R 12 , -C 0-4 Alkyl-N=SR 11 R 12 , -C 0-4 Alkyl-OS(O)2R 13 , -C 0-4 Alkyl-S(O) r R 13 , -C 0-4 Alkyl-OR 14 , -C 0-4 Alkyl-C(O)OR 14 , -C 0-4 Alkyl-C(O)SR 14 , -C 0-4 Alkyl-SC(O)R 15 , -C 0-4 Alkyl-C(O)R 15 , -C 0-4 Alkyl-OC(O)R 15 , -C 0-4 Alkyl-P(O)(R 15 2. -C 0-4 Alkyl-NR 16 R 17 , -C 0-4 Alkyl-C(=NR 16 )R 15 , -C 0-4 Alkyl-N(R 16 )-C(=NR 17 )R 15 , -C 0-4 Alkyl-C(O)NR 16 R 17 and -C 0-4 Alkyl-N(R 16 )-C(O)R 15 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=NR 10 )R 11 , -C 0-4 Alkyl-N=S(O)R 11 R 12 , -C 0-4 Alkyl-N=SR 11 R 12 , -C 0-4 Alkyl-OS(O)2R 13 , -C 0-4 Alkyl-S(O) r R 13 , -C 0-4 Alkyl-OR 14 , -C 0-4 Alkyl-C(O)OR 14 , -C 0-4 Alkyl-C(O)SR 14 , -C 0-4 Alkyl-SC(O)R 15 , -C 0-4 Alkyl-C(O)R 15 , -C 0-4 Alkyl-OC(O)R 15 , -C 0-4 Alkyl-P(O)(R 15 2. -C 0-4 Alkyl-NR 16 R 17 , -C 0-4 Alkyl-C(=NR 16 )R 15 , -C 0-4 Alkyl-N(R 16 )-C(=NR 17 )R 15 , -C 0-4 Alkyl-C(O)NR 16 R 17 and -C 0-4 Alkyl-N(R 16 )-C(O)R 15 The above groups are independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=NR 10 )R 11 , -C 0-4 Alkyl-N=S(O)R 11 R 12 , -C 0-4 Alkyl-N=SR 11 R 12 , -C 0-4 Alkyl-OS(O)2R 13 , -C 0-4 Alkyl-S(O) r R 13 , -C 0-4 Alkyl-OR 14 , -C 0-4 Alkyl-C(O)OR 14 , -C 0-4 Alkyl-C(O)SR 14 , -C 0-4 Alkyl-SC(O)R 15 , -C 0-4 Alkyl-C(O)R 15 , -C 0-4 Alkyl-OC(O)R 15 , -C 0-4 Alkyl-P(O)(R 15 2. -C 0-4 Alkyl-NR 16 R 17 , -C 0-4 Alkyl-C(=NR 16 )R 15 , -C 0-4 Alkyl-N(R 16 )-C(=NR 17 )R 15 , -C 0-4 Alkyl-C(O)NR 16 R 17 and -C 0-4 Alkyl-N(R 16 )-C(O)R 15 substituted by a substituent; R 6b , R 7b , R 8b and R 9b Selected from hydrogen, deuterium, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C 0-4 Alkyl-S(O)(=NR 10 )R 11 , -C 0-4 Alkyl-S(O) r R 13 , -C 0-4 Alkyl-C(O)OR 14 , -C 0-4 Alkyl-C(O)SR 14 , -C 0-4 Alkyl-C(O)R 15 , -C 0-4 Alkyl-P(O)(R 15 2. -C 0-4 Alkyl-C(=NR 16 )R 15 and -C 0-4 Alkyl-C(O)NR 16 R 17 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=NR 10 )R 11 , -C 0-4 Alkyl-N=S(O)R 11 R 12 , -C 0-4 Alkyl-N=SR 11 R 12 , -C 0-4 Alkyl-OS(O)2R 13 , -C 0-4 Alkyl-S(O) r R 13 , -C 0-4 Alkyl-OR 14 , -C 0-4 Alkyl-C(O)OR 14 , -C 0-4 Alkyl-C(O)SR 14 , -C 0-4 Alkyl-SC(O)R 15 , -C 0-4 Alkyl-C(O)R 15 , -C 0-4 Alkyl-OC(O)R 15 , -C 0-4 Alkyl-P(O)(R 15 2. -C 0-4 Alkyl-NR 16 R 17 , -C 0-4 Alkyl-C(=NR 16 )R 15 , -C 0-4 Alkyl-N(R 16 )-C(=NR 17 )R 15 , -C 0-4 Alkyl-C(O)NR 16 R 17 and -C 0-4 Alkyl-N(R 16 )-C(O)R 15 substituted by a substituent; Or, R 6b and R 7a Together with the part directly connected thereto, it forms a 3-8 membered heterocyclic group or a 5-8 membered heteroaryl group, wherein the above 3-8 membered heterocyclic group or the 5-8 membered heteroaryl group are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=NR 10 )R 11 , -C 0-4 Alkyl-N=S(O)R 11 R 12 , -C 0-4 Alkyl-N=SR 11 R 12 , -C 0-4 Alkyl-OS(O)2R 13 , -C 0-4 Alkyl-S(O) r R 13 , -C 0-4 Alkyl-OR 14 , -C 0-4 Alkyl-C(O)OR 14 , -C 0-4 Alkyl-C(O)SR 14 , -C 0-4 Alkyl-SC(O)R 15 , -C 0-4 Alkyl-C(O)R 15 , -C 0-4 Alkyl-OC(O)R 15 , -C 0-4 Alkyl-P(O)(R 15 2. -C 0-4 Alkyl-NR 16 R 17 , -C 0-4 Alkyl-C(=NR 16 )R 15 , -C 0-4 Alkyl-N(R 16 )-C(=NR 17 )R 15 , -C 0-4 Alkyl-C(O)NR 16 R 17 and -C 0-4 Alkyl-N(R 16 )-C(O)R 15 substituted by a substituent; Or, R 6a and R 7b Together with the part directly connected thereto, it forms a 3-8 membered heterocyclic group or a 5-8 membered heteroaryl group, wherein the above 3-8 membered heterocyclic group or the 5-8 membered heteroaryl group are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-S(O)(=NR 10 )R 11 , -C 0-4 Alkyl-N=S(O)R 11 R 12 , -C 0-4 Alkyl-N=SR 11 R 12 , -C 0-4 Alkyl-OS(O)2R 13 , -C 0-4 Alkyl-S(O) r R 13 , -C 0-4 Alkyl-OR 14 , -C 0-4 Alkyl-C(O)OR 14 , -C 0-4 Alkyl-C(O)SR 14 , -C 0-4 Alkyl-SC(O)R 15 , -C 0-4 Alkyl-C(O)R 15 , -C 0-4 Alkyl-OC(O)R 15 , -C 0-4 Alkyl-P(O)(R 15 2. -C 0-4 Alkyl-NR 16 R 17 , -C 0-4 Alkyl-C(=NR 16 )R 15 , -C 0-4 Alkyl-N(R 16 )-C(=NR 17 )R 15 , -C 0-4 Alkyl-C(O)NR 16 R 17 and -C 0-4 Alkyl-N(R 16 )-C(O)R 15 substituted by a substituent; Among them, R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 and r as described in claim 1.

3. The compound of formula (I) according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: Each R 10 are each independently selected from hydrogen, deuterium, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C 0-4 Alkyl-S(O) r R 13 , -C 0-4 Alkyl-C(O)OR 14 , -C 0-4 Alkyl-C(O)R 15 and -C 0-4 Alkyl-C(O)NR 16 R 17 The above groups are optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C 0-4 Alkyl-S(O) r R 13 , -C 0-4 Alkyl-OR 14 , -C 0-4 Alkyl-C(O)OR 14 , -C 0-4 Alkyl-C(O)R 15 , -C 0-4 Alkyl-OC(O)R 15 , -C 0-4 Alkyl-NR 16 R 17 , -C 0-4 Alkyl-C(=NR 16 )R 15 , -C 0-4 Alkyl-N(R 16 )-C(=NR 17 )R 15 , -C 0-4 Alkyl-C(O)NR 16 R 17 and -C 0-4 Alkyl-N(R 16 )-C(O)R 15 substituted by a substituent; Each R 11 and each R 12 are each independently selected from hydrogen, deuterium, hydroxyl, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl and 5-8 membered heteroaryl, or, R 11 and R 12 Together with the sulfur atom directly connected thereto, it forms a 3-8 membered heterocyclic group, wherein the above group is optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C 0-4 Alkyl-S(O) r R 13 , -C 0-4 Alkyl-OR 14 , -C 0-4 Alkyl-C(O)OR 14 , -C 0-4 Alkyl-C(O)R 15 , -C 0-4 Alkyl-OC(O)R 15 , -C 0-4 Alkyl-NR 16 R 17 , -C 0-4 Alkyl-C(=NR 16 )R 15 , -C 0-4 Alkyl-N(R 16 )-C(=NR 17 )R 15 , -C 0-4 Alkyl-C(O)NR 16 R 17 and -C 0-4 Alkyl-N(R 16 )-C(O)R 15 substituted by a substituent; Each R 13 are independently selected from hydrogen, deuterium, hydroxyl, C 1-4 Alkyl, C 2-4 Alkenyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl and -NR 16 R 17 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, hydroxyl, =O, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy and -NR 16 R 17 substituted by a substituent; Each R 14 independently selected from hydrogen, deuterium, C 1-4 Alkyl, C 2-4 Alkenyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl and 5-8 membered heteroaryl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, cyano, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy and -NR 16 R 17 substituted by a substituent; Each R 15 are independently selected from hydrogen, deuterium, hydroxyl, C 1-4 Alkyl, C 1-4 Alkoxy, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy and -NR 16 R 17 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, cyano, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy and -NR 16 R 17 substituted by a substituent; Each R 16 and R 17 are each independently selected from hydrogen, deuterium, hydroxyl, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, sulfinyl, sulfonyl, methylsulfonyl, isopropylsulfonyl, cyclopropylsulfonyl, p-toluenesulfonyl, aminosulfonyl, dimethylaminosulfonyl and C 1-4 Alkanoyl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, amino, mono C 1-4 Alkylamino, di-C 1-4 Alkylamino and C 1-4 substituted with an alkanoyl substituent; Or, R 16 and R 17 Together with the nitrogen atom directly connected thereto, a 4-6 membered heterocyclic group or a 5-8 membered heteroaryl group is formed, wherein the 4-6 membered heterocyclic group or the 5-8 membered heteroaryl group is optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 ring Alkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, amino, mono C 1-4 Alkylamino, di-C 1-4 Alkylamino and C 1-4 The alkanoyl group is substituted with an alkanoyl substituent.

4. The compound of formula (I) according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: The compound of formula (I) is a compound of formula (IIa1), a compound of formula (IIa2), a compound of formula (IIa3) or a compound of formula (IIa4): Wherein, each X1 is independently CR4 or N; Each W is independently N or CR 8a ; Each Q is independently N or CR 9a ; Each ring A is independently C 5-8 Cycloalkyl or 5-8 membered heterocyclic group; Each R1 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -S(O)(=NR 10 )R 11 、-N=S(O)R 11 R 12 、-N=SR 11 R 12 、-OS(O)2R 13 、-S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)SR 14 、-SC(O)R 15 、-C(O)R 15 、-OC(O)R 15 、-P(O)(R 15 )2.-NR 16 R 17 、-C(=NR 16 )R 15 、-N(R 16 )-C(=NR 17 )R 15 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -S(O)(=NR 10 )R 11 、-N=S(O)R 11 R 12 、-N=SR 11 R 12 、-OS(O)2R 13 、-S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)SR 14 、-SC(O)R 15 、-C(O)R 15 、-OC(O)R 15 、-P(O)(R 15 )2.-NR 16 R 17 、-C(=NR 16 )R 15 、-N(R 16 )-C(=NR 17 )R 15 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 substituted by a substituent; Each R2 is independently selected from halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 1-4 Alkoxy, halogen substituted C 1-4 Alkoxy, deuterium substituted C 1-4 Alkoxy, -SF5, -C(O)OR 14 、-C(O)R 15 、-OC(O)R 15 、-NR 16 R 17 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 ; Each R3 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -SF5, -OR 14 and-NR 16 R 17 ; Each R4 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -SF5, -OR 14 and-NR 16 R 17 ; Each R5 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -SF5, -OR 14 and-NR 16 R 17 ; Each R 6a and each R 7a are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -S(O)(=NR 10 )R 11 、-N=S(O)R 11 R 12 、-N=SR 11 R 12 、-OS(O)2R 13 、-S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)SR 14 、-SC(O)R 15 、-C(O)R 15 、-OC(O)R 15 、-P(O)(R 15 )2.-NR 16 R 17 、-C(=NR 16 )R 15 、-N(R 16 )-C(=NR 17 )R 15 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -S(O)(=NR 10 )R 11 、-N=S(O)R 11 R 12 、-N=SR 11 R 12 、-OS(O)2R 13 、-S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)SR 14 、-SC(O)R 15 、-C(O)R 15 、-OC(O)R 15 、-P(O)(R 15 )2.-NR 16 R 17 、-C(=NR 16 )R 15 、-N(R 16 )-C(=NR 17 )R 15 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 The above groups are independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -S(O)(=NR 10 )R 11 、-N=S(O)R 11 R 12 、-N=SR 11 R 12 、-OS(O)2R 13 、-S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)SR 14 、-SC(O)R 15 、-C(O)R 15 、-OC(O)R 15 、-P(O)(R 15 )2.-NR 16 R 17 、-C(=NR 16 )R 15 、-N(R 16 )-C(=NR 17 )R 15 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 substituted by a substituent; Each R 6b and each R 7b are each independently selected from hydrogen, deuterium, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -S(O)(=NR 10 )R 11 、-S(O) r R 13 、-C(O)OR 14 、-C(O)SR 14 、-C(O)R 15 、-P(O)(R 15 )2, -C(=NR 16 )R 15 and -C(O)NR 16 R 17 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -S(O)(=NR 10 )R 11 、-N=S(O)R 11 R 12 、-N=SR 11 R 12 、-OS(O)2R 13 、-S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)SR 14 、-SC(O)R 15 、-C(O)R 15 、-OC(O)R 15 、-P(O)(R 15 )2.-NR 16 R 17 、-C(=NR 16 )R 15 、-N(R 16 )-C(=NR 17 )R 15 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 substituted by a substituent; Alternatively, in the compound of formula (IIa1) or the compound of formula (IIa3), R 6b and R 7a Together with the part directly connected thereto, it forms a 3-8 membered heterocyclic group or a 5-8 membered heteroaryl group, wherein the above 3-8 membered heterocyclic group or the 5-8 membered heteroaryl group are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, =O, =S, -SF5, -S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)R 15 、-OC(O)R 15 and-NR 16 R 17 substituted by a substituent; Alternatively, in the compound of formula (IIa2) or the compound of formula (IIa4), R 6a and R 7b Together with the part directly connected thereto, it forms a 3-8 membered heterocyclic group or a 5-8 membered heteroaryl group, wherein the above 3-8 membered heterocyclic group or the 5-8 membered heteroaryl group are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, =O, =S, -SF5, -S(O) r R 13 、-OR 14 、-C(O)OR 14 , -C(O)R 15 、-OC(O)R 15 and-NR 16 R 17 substituted by a substituent; Each R 8a and R 9a are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -S(O)(=NR 10 )R 11 、-N=S(O)R 11 R 12 、-N=SR 11 R 12 、-OS(O)2R 13 、-S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)SR 14 、-SC(O)R 15 、-C(O)R 15 、-OC(O)R 15 、-P(O)(R 15 )2.-NR 16 R 17 、-C(=NR 16 )R 15 、-N(R 16 )-C(=NR 17 )R 15 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -S(O)(=NR 10 )R 11 、-N=S(O)R 11 R 12 、-N=SR 11 R 12 、-OS(O)2R 13 、-S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)SR 14 、-SC(O)R 15 、-C(O)R 15 、-OC(O)R 15 、-P(O)(R 15 )2.-NR 16 R 17 、-C(=NR 16 )R 15 、-N(R 16 )-C(=NR 17 )R 15 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 substituted by a substituent; Among them, R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , m and r as described in claim 1.

5. The compound of formula (I) according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: The compound of formula (I) is the following formula (IIIa1), formula (IIIa2), formula (IIIa3) or formula (IIIa4): Wherein, each X1 is independently CR4 or N; Each W is independently N or CR 8a ; Each Q is independently N or CR 9a ; Each U is independently NR 1a , CR 1b R 1c , O or S; Each p is independently 1, 2 or 3; each q is independently 0, 1, 2 or 3; Each R1 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -SF5, -S(O)(=NR 10 )R 11 、-N=S(O)R 11 R 12 、-S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)R 15 、-NR 16 R 17 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, =O, =S, -SF5, -S(O)(=NR 10 )R 11 、-N=S(O)R 11 R 12 、-S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)R 15 、-NR 16 R 17 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 substituted by a substituent; Each R 1a are each independently selected from hydrogen, deuterium, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -S(O)(=NR 10 )R 11 、-S(O) r R 13 、-C(O)OR 14 、-C(O)R 15 and -C(O)NR 16 R 17 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, =O, =S, -SF5, -S(O)(=NR 10 )R 11 、-N=S(O)R 11 R 12 、-S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)R 15 、-NR 16 R 17 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 substituted by a substituent; Each R 1b and R 1c are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -SF5, -S(O)(=NR 10 )R 11 、-N=S(O)R 11 R 12 、-S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)R 15 、-NR 16 R 17 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, =O, =S, -SF5, -S(O)(=NR 10 )R 11 、-N=S(O)R 11 R 12 、-S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)R 15 、-NR 16 R 17 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 substituted by a substituent; Each R2 is independently selected from halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 1-4 Alkoxy, halogen substituted C 1-4 Alkoxy, deuterium substituted C 1-4 Alkoxy, -NR 16 R 17 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 ; Each R4 is independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, n-propoxy, isopropoxy, trifluoromethyl, trideuteriomethyl, trifluoromethoxy, trideuteriomethoxy, vinyl, ethynyl, cyclopropyl, cyclobutyl, cyclopropyloxy, cyclobutyloxy, oxetanyl, azetidinyl, -SF5, hydroxyl, amino, methylamino and dimethylamino; Each R5 is independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, n-propoxy, isopropoxy, trifluoromethyl, trideuteriomethyl, trifluoromethoxy, trideuteriomethoxy, vinyl, ethynyl, cyclopropyl, cyclobutyl, cyclopropyloxy, cyclobutyloxy, oxetanyl, azetidinyl, -SF5, hydroxyl, amino, methylamino and dimethylamino; Each R 6a and each R 7a are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -SF5, -S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)R 15 、-OC(O)R 15 、-NR 16 R 17 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, =O, =S, -SF5, -S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)R 15 、-OC(O)R 15 、-NR 16 R 17 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 The above groups are independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, =O, =S, -SF5, -S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)R 15 、-OC(O)R 15 、-NR 16 R 17 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 substituted by a substituent; Each R 6b and each R 7b are each independently selected from hydrogen, deuterium, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -S(O) r R 13 、-C(O)OR 14 、-C(O)R 15 and -C(O)NR 16 R 17 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, =O, =S, -SF5, -S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)R 15 、-OC(O)R 15 、-NR 16 R 17 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 substituted by a substituent; Alternatively, in the compound of formula (IIIa1) or the compound of formula (IIIa3), R 6b and R 7a Together with the part directly connected thereto, it forms a 3-8 membered heterocyclic group or a 5-8 membered heteroaryl group, wherein the above 3-8 membered heterocyclic group or the 5-8 membered heteroaryl group are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, =O, =S, -SF5, -S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)R 15 、-OC(O)R 15 and-NR 16 R 17 substituted by a substituent; Alternatively, in the compound of formula (IIIa2) or the compound of formula (IIIa4), R 6a and R 7b Together with the part directly connected thereto, it forms a 3-8 membered heterocyclic group or a 5-8 membered heteroaryl group, wherein the above 3-8 membered heterocyclic group or the 5-8 membered heteroaryl group are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, =O, =S, -SF5, -S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)R 15 、-OC(O)R 15 and-NR 16 R 17 substituted by a substituent; Each R 8a and R 9a are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -SF5, -S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)R 15 、-OC(O)R 15 、-NR 16 R 17 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, =O, =S, -SF5, -S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)R 15 、-OC(O)R 15 、-NR 16 R 17 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 substituted by a substituent; Among them, R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , m and r as described in claim 1.

6. The compound of formula (I) according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: The compound of formula (I) is a compound of formula (IVa1), formula (IVa2), formula (IVa3) or formula (IVa4): wherein each X1 is independently CH or N; Each U is independently NR 1a , CH2, O or S; each p is independently 1 or 2; Each R 1a are each independently selected from hydrogen, deuterium, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, methylsulfinyl, methylsulfonyl, isopropylsulfonyl, cyclopropylsulfonyl, aminosulfonyl and C 1-4 Alkanoyl, the above groups are Optionally further substituted with one or more selected from deuterium, halogen, cyano, hydroxyl, carboxyl, C 1-4 Alkyl, C 1-4 Alkoxy, halogen substituted C 1-4 Alkyl, halogen substituted C 1-4 Alkoxy, deuterium substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyloxy, =O, =S, -NR 16 R 17 and -C(O)NR 16 R 17 substituted by a substituent; Each R2 is independently selected from halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 1-4 Alkoxy, halogen substituted C 1-4 Alkoxy, deuterium substituted C 1-4 Alkoxy, -NR 16 R 17 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 ; Each R5 is independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, methoxy, trifluoromethyl, trifluoromethoxy, trifluoroethoxy, trideuteriomethyl, trideuteriomethoxy, cyclopropyl, cyclopropyloxy, hydroxy, amino, methylamino and dimethylamino; Each R 6a and each R 7a are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, methylsulfinyl, methylsulfonyl, isopropylsulfonyl, cyclopropylsulfonyl, aminosulfonyl, amino, methylamino, dimethylamino, C 1-4 Alkanoyl and -C(O)NR 16 R 17 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, hydroxyl, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyloxy, =O, =S, -NR 16 R 17 and -C(O)NR 16 R 17 The above groups are independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, hydroxyl, C 1-4 Alkyl, C 1-4 Alkoxy, halogen substituted C 1-4 Alkyl, halogen substituted C 1-4 Alkoxy, deuterium substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyloxy, =O, =S, -NR 16 R 17 and -C(O)NR 16 R 17 substituted by a substituent; Each R 6b and each R 7b are each independently selected from hydrogen, deuterium, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, methylsulfinyl, methylsulfonyl, isopropylsulfonyl, cyclopropylsulfonyl, aminosulfonyl and C 1-4 Alkanoyl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, hydroxyl, C 1-4 Alkyl, C 1-4 Alkoxy, halogen substituted C 1-4 Alkyl, halogen substituted C 1-4 Alkoxy, deuterium substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyloxy, =O, =S, -NR 16 R 17 and -C(O)NR 16 R 17 substituted by a substituent; Alternatively, in the compound of formula (IVa1) or the compound of formula (IVa3), R 6b and R 7a Together with the part directly connected thereto, a 3-8 membered heterocyclic group or a 5-8 membered heteroaryl group is formed, wherein the above 3-8 membered heterocyclic group or the 5-8 membered heteroaryl group is independently optionally further substituted by one or more selected from deuterium, halogen, cyano, hydroxyl, C 1-4 Alkyl, C 1-4 Alkoxy, halogen substituted C 1-4 Alkyl, halogen substituted C 1-4 Alkoxy, deuterium substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyloxy, =O, =S and -NR 16 R 17 substituted by a substituent; Alternatively, in the compound of formula (IVa2) or the compound of formula (IVa4), R 6a and R 7b Together with the part directly connected thereto, a 3-8 membered heterocyclic group or a 5-8 membered heteroaryl group is formed, wherein the above 3-8 membered heterocyclic group or the 5-8 membered heteroaryl group is independently optionally further substituted by one or more selected from deuterium, halogen, cyano, hydroxyl, C 1-4 Alkyl, C 1-4 Alkoxy, halogen substituted C 1-4 Alkyl, halogen substituted C 1-4 Alkoxy, deuterium substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyloxy, =O, =S and -NR 16 R 17 substituted by a substituent; Among them, R 13 , R 14 , R 15 , R 16 and R 17 As claimed in claim 1.

7. The compound of formula (I) according to claim 6, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: Each U is independently NR 1a , CH2, O or S; Each R 1a are each independently selected from hydrogen, deuterium, C 1-4 Alkyl, C 3-6 Cycloalkyl, methylsulfonyl and isopropylsulfonyl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 The alkyl group may be substituted by cycloalkyl, -C(O)NH2, -C(O)NHCH3 and -C(O)N(CH3)2 substituents.

8. The compound of formula (I) according to claim 6, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: Each R5 is independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, methoxy, trifluoromethyl, trifluoromethoxy, trifluoroethoxy, trideuteriomethyl, trideuteriomethoxy and cyclopropyl.

9. The compound of formula (I) according to claim 6, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: R 6b Selected from hydrogen, deuterium, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, methylsulfonyl and C 1-4 Alkanoyl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, hydroxyl, C 1-4 Alkyl, C 1-4 Alkoxy, halogen substituted C 1-4 Alkyl, halogen substituted C 1-4 Alkoxy, deuterium substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyl and -NR 16 R 17 substituted by a substituent; R 7a Selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, methylsulfonyl, amino, methylamino, dimethylamino, C 1-4 Alkanoyl and -C(O)NR 16 R 17 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, hydroxyl, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyl and -NR 16 R 17 The above groups are independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, hydroxyl, C 1-4 Alkyl, C 1-4 Alkoxy, halogen substituted C 1-4 Alkyl, halogen substituted C 1-4 Alkoxy, deuterium substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyl and -NR 16 R 17 substituted by a substituent; Or, R 6b and R 7a Together with the part directly connected thereto, a 3-8 membered heterocyclic group is formed, wherein the 3-8 membered heterocyclic group is optionally further substituted with one or more selected from deuterium, halogen, cyano, hydroxyl, C 1-4 Alkyl, C 1-4 Alkoxy, halogen substituted C 1-4 Alkyl, halogen substituted C 1-4 Alkoxy, deuterium substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyl and -NR 16 R 17 substituted by a substituent; Among them, R 16 and R 17 As described in claim 6.

10. The compound of formula (I) according to claim 6, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: R 6a Selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, methylsulfonyl, amino, methylamino, dimethylamino, C 1-4 Alkanoyl and -C(O)NR 16 R 17 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, hydroxyl, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyl and -NR 16 R 17 The above groups are independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, hydroxyl, C 1-4 Alkyl, C 1-4 Alkoxy, halogen substituted C 1-4 Alkyl, halogen substituted C 1-4 Alkoxy, deuterium substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyl and -NR 16 R 17 substituted by a substituent; R 7b Selected from hydrogen, deuterium, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, methylsulfonyl and C 1-4 Alkanoyl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, hydroxyl, C 1-4 Alkyl, C 1-4 Alkoxy, halogen substituted C 1-4 Alkyl, halogen substituted C 1-4 Alkoxy, deuterium substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyl and -NR 16 R 17 substituted by a substituent; Or, R 6a and R 7b Together with the part directly connected thereto, a 3-8 membered heterocyclic group is formed, wherein the 3-8 membered heterocyclic group is optionally further substituted with one or more selected from deuterium, halogen, cyano, hydroxyl, C 1-4 Alkyl, C 1-4 Alkoxy, halogen substituted C 1-4 Alkyl, halogen substituted C 1-4 Alkoxy, deuterium substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyl and -NR 16 R 17 substituted by a substituent; Among them, R 16 and R 17 As described in claim 6.

11. The compound of formula (I) according to claim 6, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: Each R 16 and R 17 are each independently selected from hydrogen, deuterium, hydroxyl, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, sulfinyl, sulfonyl, methylsulfonyl, isopropylsulfonyl, cyclopropylsulfonyl, p-toluenesulfonyl, aminosulfonyl, dimethylaminosulfonyl and C 1-4 Alkanoyl; Or, R 16 and R 17 Together with the nitrogen atom directly connected thereto, it forms a 4-6 membered heterocyclic group, wherein the 4-6 membered heterocyclic group is optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 The cycloalkyl group is substituted by a substituent of a 3- to 6-membered heterocyclic group.

12. The compound of formula (I) according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: The compound of formula (I) is a compound of formula (IIb1) or formula (IIb2): Wherein, each X1 is independently CR4 or N; Each W is independently N or CR 8a ; Each Q is independently N or CR 9a ; Each ring A is independently phenyl or a 5-6-membered heteroaryl group; Each R1 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-8 membered heterocyclic group, C 3-6 Cycloalkyl substituted C 1-4 Alkyl, 3-6 membered heterocyclic substituted C 1-4 Alkyl, -SF5, -S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)R 15 、-OC(O)R 15 、-NR 16 R 17 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, =O, =S, -SF5, -S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)R 15 、-OC(O)R 15 、-NR 16 R 17 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 The above groups are independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen Replace C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)R 15 、-OC(O)R 15 、-NR 16 R 17 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 substituted by a substituent; Each R4 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -SF5, -OR 14 and-NR 16 R 17 ; Each R5 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -SF5, -OR 14 and-NR 16 R 17 ; R 6a and R 7a are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -SF5, -S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)R 15 、-OC(O)R 15 、-NR 16 R 17 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, =O, =S, -SF5, -S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)R 15 、-OC(O)R 15 、-NR 16 R 17 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 The above groups are independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, =O, =S, -SF5, -S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)R 15 、-OC(O)R 15 、-NR 16 R 17 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 substituted by a substituent; R 6b and R 7b are each independently selected from hydrogen, deuterium, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -S(O) r R 13 、-C(O)OR 14 、-C(O)R 15 and -C(O)NR 16 R 17 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, =O, =S, -SF5, -S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)R 15 、-OC(O)R 15 、-NR 16 R 17 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 substituted by a substituent; Alternatively, in the compound of formula (IIb1), R 6b and R 7a Together with the part directly connected thereto, it forms a 3-8 membered heterocyclic group or a 5-8 membered heteroaryl group, wherein the above 3-8 membered heterocyclic group or the 5-8 membered heteroaryl group are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, =O, =S, -SF5, -S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)R 15 、-OC(O)R 15 and-NR 16 R 17 substituted by a substituent; Alternatively, in the compound of formula (IIb2), R 6a and R 7b Together with the part directly connected thereto, it forms a 3-8 membered heterocyclic group or a 5-8 membered heteroaryl group, wherein the above 3-8 membered heterocyclic group or the 5-8 membered heteroaryl group are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, =O, =S, -SF5, -S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)R 15 、-OC(O)R 15 and-NR 16 R 17 substituted by a substituent; Each R 8a and R 9a are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -SF5, -S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)R 15 、-OC(O)R 15 、-NR 16 R 17 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkyne Base, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, =O, =S, -SF5, -S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)R 15 、-OC(O)R 15 、-NR 16 R 17 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 substituted by a substituent; Among them, R 13 , R 14 , R 15 , R 16 , R 17 , m and r as described in claim 1.

13. The compound of formula (I) according to claim 12, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: The compound of formula (I) is a compound of formula (IIIb1) or formula (IIIb2): wherein each X1 is independently CH or N; Ring A is selected from phenyl, pyridyl, pyrimidinyl, pyridazinyl, triazinyl, furanyl, thienyl, imidazolyl, triazolyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl and isothiazolyl; Each R1 is independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-8 membered heterocyclic group, C 3-6 Cycloalkyl substituted C 1-4 Alkyl, 3-6 membered heterocyclic substituted C 1-4 Alkyl-C(O)R 15 、-NR 16 R 17 , and -C(O)NR 16 R 17 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, hydroxy substituted C 1-4 Alkyl, cyano substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, =O, =S, -SF5, -S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)R 15 、-OC(O)R 15 、-NR 16 R 17 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 substituted by a substituent; Each R5 is independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, methoxy, trifluoromethyl, trifluoromethoxy, trifluoroethoxy, trideuteriomethyl, trideuteriomethoxy, cyclopropyl, cyclopropyloxy, hydroxy, amino, methylamino and dimethylamino; Among them, R 6a , R 6b , R 7a , R 7b , R 13 , R 14 , R 15 , R 16 , R 17 , m and r as described in claim 12.

14. The compound of formula (I) according to claim 13, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: R 6b Selected from hydrogen, deuterium, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, methylsulfinyl, methylsulfonyl, isopropylsulfonyl, cyclopropylsulfonyl, aminosulfonyl and C 1-4 Alkanoyl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, hydroxyl, C 1-4 Alkyl, C 1-4 Alkoxy, halogen substituted C 1-4 Alkyl, halogen substituted C 1-4 Alkoxy, deuterium substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyloxy, =O, =S, -NR 16 R 17 and -C(O)NR 16 R 17 substituted by a substituent; R 7a Selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, methylsulfinyl, methylsulfonyl, isopropylsulfonyl, cyclopropylsulfonyl, aminosulfonyl, amino, methylamino, dimethylamino, C 1-4 Alkanoyl and -C(O)NR 16 R 17 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, hydroxyl, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyloxy, =O, =S, -NR 16 R 17 and -C(O)NR 16 R 17 The above groups are independently optionally further One or more selected from deuterium, halogen, cyano, hydroxyl, C 1-4 Alkyl, C 1-4 Alkoxy, halogen substituted C 1-4 Alkyl, halogen substituted C 1-4 Alkoxy, deuterium substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyloxy, =O, =S, -NR 16 R 17 and -C(O)NR 16 R 17 substituted by a substituent; Or, R 6b and R 7a Together with the part directly connected thereto, a 3-8 membered heterocyclic group is formed, wherein the 3-8 membered heterocyclic group is independently optionally further substituted with one or more selected from deuterium, halogen, cyano, hydroxyl, C 1-4 Alkyl, C 1-4 Alkoxy, halogen substituted C 1-4 Alkyl, halogen substituted C 1-4 Alkoxy, deuterium substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyloxy, =O, =S and -NR 16 R 17 substituted by a substituent; Among them, R 16 and R 17 As described in claim 13.

15. The compound of formula (I) according to claim 13, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: R 6a Selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, methylsulfinyl, methylsulfonyl, isopropylsulfonyl, cyclopropylsulfonyl, aminosulfonyl, amino, methylamino, dimethylamino, C 1-4 Alkanoyl and -C(O)NR 16 R 17 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, hydroxyl, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyloxy, =O, =S, -NR 16 R 17 and -C(O)NR 16 R 17 The above groups are independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, hydroxyl, C 1-4 Alkyl, C 1-4 Alkoxy, halogen substituted C 1-4 Alkyl, halogen substituted C 1-4 Alkoxy, deuterium substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyloxy, =O, =S, -NR 16 R 17 and -C(O)NR 16 R 17 substituted by a substituent; R 7b Selected from hydrogen, deuterium, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, methylsulfinyl, methylsulfonyl, isopropylsulfonyl, cyclopropylsulfonyl, aminosulfonyl and C 1-4 Alkanoyl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, hydroxyl, C 1-4 Alkyl, C 1-4 Alkoxy, halogen substituted C 1-4 Alkyl, halogen substituted C 1-4 Alkoxy, deuterium substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyloxy, =O, =S, -NR 16 R 17 and -C(O)NR 16 R 17 substituted by a substituent; Or, R 6a and R 7b Together with the part directly connected thereto, a 3-8 membered heterocyclic group is formed, wherein the 3-8 membered heterocyclic group is independently optionally further substituted with one or more selected from deuterium, halogen, cyano, hydroxyl, C 1-4 Alkyl, C 1-4 Alkoxy, halogen substituted C 1-4 Alkyl, halogen substituted C 1-4 Alkoxy, deuterium substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyloxy, =O, =S and -NR 16 R 17 substituted by a substituent; Among them, R 16 and R 17 As described in claim 13.

16. The compound of formula (I) according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: Each R 13 are independently selected from hydrogen, deuterium, hydroxyl, C 1-4 Alkyl, 3-6 membered heterocyclic group and -NR 16 R 17 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, hydroxyl, =O, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyl and -NR 16 R 17 substituted by a substituent; Each R 14 independently selected from hydrogen, deuterium, C 1-4 Alkyl and 3-6 membered heterocyclic groups, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, cyano, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyl and -NR 16 R 17 substituted by a substituent; Each R 15 are independently selected from hydrogen, deuterium, hydroxyl, C 1-4 Alkyl, C 1-4 Alkoxy, C 2-4 Alkenyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyl and -NR 16 R 17 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, cyano, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyl and -NR 16 R 17 substituted by a substituent; Among them, R 16 and R 17 As described in claim 13.

17. The compound of formula (I) according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: Each R 16 and R 17 are each independently selected from hydrogen, deuterium, hydroxyl, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, sulfinyl, sulfonyl, methylsulfonyl, isopropylsulfonyl, cyclopropylsulfonyl, p-toluenesulfonyl, aminosulfonyl, dimethylaminosulfonyl and C 1-4 Alkanoyl; Or, R 16 and R 17 Together with the nitrogen atom directly connected thereto, it forms a 4-6 membered heterocyclic group, wherein the 4-6 membered heterocyclic group is optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 3-6 The cycloalkyl group is substituted by a substituent of a 3- to 6-membered heterocyclic group.

18. The compound of formula (I) according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: Selected from the following compounds:

19. A pharmaceutical composition comprising a compound of formula (I) according to any one of claims 1 to 18, a stereoisomer thereof or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

20. Use of a compound of formula (I) according to any one of claims 1 to 18, a stereoisomer thereof or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating at least part of a tumor associated with CDK; preferably, the tumor is cancer.

21. Use of a compound of formula (I) according to any one of claims 1 to 18, a stereoisomer thereof or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating breast cancer, malignant brain tumors, colon cancer, small cell lung cancer, non-small cell lung cancer, bladder cancer, ovarian cancer, prostate cancer, chronic lymphocytic leukemia, lymphoma, myeloma, acute myeloid leukemia, secondary pancreatic cancer or secondary brain metastasis that is at least partially associated with CDK.

22. A compound of formula (I) according to any one of claims 1 to 18, a stereoisomer thereof or a pharmaceutically acceptable salt thereof, for use in treating at least part of a tumor associated with CDK; preferably, the tumor is cancer.

23. A compound of formula (I) according to any one of claims 1 to 18, a stereoisomer thereof or a pharmaceutically acceptable salt thereof, for use in treating breast cancer, malignant brain tumors, colon cancer, small cell lung cancer, non-small cell lung cancer, bladder cancer, ovarian cancer, prostate cancer, chronic lymphocytic leukemia, lymphoma, myeloma, acute myeloid leukemia, secondary pancreatic cancer or secondary brain metastasis that is at least partially associated with CDK.

Images